Oligosaccharide-protein complexes

Novel oligosaccharide-protein complexes with optimized glycosidic linkages and linkers address the challenges of improving enzyme receptor affinity and synthesis costs, enhancing therapeutic efficacy for LSDs.

JP7590515B2Active Publication Date: 2024-11-26GENZYME CORP
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2023136066
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2008-12-16
Filing Date
2023-08-24
Publication Date
2024-11-26
Estimated Expiration
2029-12-11

AI Technical Summary

Technical Problem

Current methods for treating lysosomal storage diseases (LSDs) face challenges in improving the therapeutic efficacy of enzyme replacement therapy by enhancing the affinity of lysosomal enzymes for mannose-6-phosphate receptors and ensuring consistent biological function of oligosaccharide-protein conjugates, while existing oligosaccharides are difficult and expensive to synthesize.

Method used

Development of novel oligosaccharide-protein complexes with specific glycosidic linkages and linkers, optimized for high affinity to mannose-6-phosphate receptors, and synthesized using stereoselective methods to ensure consistent biological activity.

Benefits of technology

The novel complexes demonstrate enhanced uptake by target cells, maintaining or improving enzymatic activity, leading to better therapeutic outcomes for LSDs, and are more cost-effective to produce on a commercial scale.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590515000077
    Figure 0007590515000077
  • Figure 0007590515000078
    Figure 0007590515000078
  • Figure 0007590515000079
    Figure 0007590515000079
Patent Text Reader

Abstract

To provide saccharides useful in producing a medicament for treatment of lysosomal storage disease.SOLUTION: The invention provides compounds represented by formula 64 or 66.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 61 / 122,851, which is incorporated herein by reference in its entirety.

[0002] The present invention relates generally to oligosaccharide-protein conjugates comprising individual oligosaccharides, and compositions comprising such conjugates. The present invention further relates to methods of treating lysosomal storage diseases using oligosaccharide-lysosomal enzyme conjugates. [Background technology]

[0003] Lysosomal storage diseases (LSDs) are a group of rare metabolic disorders involving defective activity of lysosomal hydrolases and include more than 40 genetic disorders. The hallmark of LSDs is the abnormal accumulation of lysosomal metabolites, leading to the formation of numerous distended lysosomes.

[0004] LSD can be treated by administering to patients an activated version of the defective enzyme, a method called enzyme replacement therapy (ERT). When the replacement enzyme, which has mannose-6-phosphate (M6P) at its terminus, is administered, it is taken up into target cells by endocytosis via the cell surface-bound cation-independent M6P receptor (CI-MPR) and acts on the lysosome.

[0005] Generally, replacement enzymes with low phosphorylation levels are not effectively taken up by the M6P receptor on the cell surface and therefore cannot act on functional lysosomes, so low mannose phosphorylation levels may have serious and detrimental effects on the therapeutic efficacy of replacement enzymes.

[0006] Methods have been developed to increase the M6P content of replacement enzymes. For example, U.S. Patent Nos. 6,534,300, 6,670,165, and 6,861,242 describe enzymatic phosphorylation of terminal mannose residues. As another example, U.S. Patent No. 7,001,994 describes a method for conjugating M6P-containing oligosaccharides to glycoproteins. The complex of lysosomal enzyme acid α-glucosidase (GAA) and bis-M6P oligosaccharides produced by the method was found to be more effective in reducing skeletal and cardiac muscle glycogen than recombinant human GAA in a mouse model of Pompe disease. Pompe disease is an autosomal recessive muscle disease caused by a metabolic defect in GAA and is characterized by the accumulation of lysosomal glycogen. Similarly, Zhu et al. described the conjugation of a synthetic bisM6P oligosaccharide (Formula A) to GAA (Zhu et al., Biochem. J. 389:619-628 (2005)), which was created by removing one branch, shortening another branch, and phosphorylating the terminal mannose residue from the native triantennary Man9 core structure of the N-linked glycan (Formula B).

[0007] [ka]

[0008] The resulting conjugates bound with higher affinity to the CI-MPR, were internalized more effectively, and had near-normal enzyme activity in L6 myoblasts. However, despite this success, it remains important to identify novel oligosaccharides that, when conjugated to lysosomal enzymes, have improved affinity to the CI-MPR and / or more effective cellular uptake while still having normal or near-normal enzyme activity. However, improved internalization alone does not necessarily result in better therapeutic outcomes. With certain conjugation methods and oligosaccharides, the resulting conjugates have low enzyme activity. It is therefore desirable to identify oligosaccharides and conjugates that can improve the therapeutic outcome of LSD patients.

[0009] Moreover, certain oligosaccharides, such as those shown in formulas A and B, can be difficult and expensive to synthesize. Moreover, stereoselectively creating β-linked glycans has been a challenging problem in glycochemistry. For commercial-scale use, alternative oligosaccharides and synthesis methods may be more practical. There is a need for further optimization of the methods used to produce oligosaccharide-protein conjugates. Especially for therapeutic purposes, conjugate production should not be highly heterogeneous, as this may result in inconsistent biological functions. Various factors of the conjugate, such as the oligosaccharide and linker used, the conjugation method, the purification method, and the formulation, can affect the therapeutic effect. Summary of the Invention

[0010] Accordingly, certain embodiments of the invention comprise a compound comprising: (1) a protein; and (2) a compound of formula I:

[0011] [ka]

[0012] [In the formula, a=α1,2;α1,3;α1,4; or α1,6; b=α1,2;α1,3; or α1,4; c=α1,2;α1,3;α1,4; or α1,6; and d = α, β, or a mixture of α and β] The present invention provides an oligosaccharide-protein conjugate comprising an oligosaccharide represented by the formula:

[0013] Another embodiment of the invention is a compound comprising: (1) a protein; and (2) a compound of formula II:

[0014] [ka]

[0015] [In the formula, e=α1,2;α1,3;α1,4; or α1,6; and f=α, β, or a mixture of α and β; where e = α1,6, f = α or a mixture of α and β. The present invention provides an oligosaccharide-protein conjugate comprising an oligosaccharide represented by the formula:

[0016] Yet another embodiment of the present invention is a method for producing a compound comprising: (1) a protein; and (2) a compound of formula III:

[0017] [ka]

[0018] [In the formula, g=α1,2;α1,3; or α1,4; h=α1,2;α1,3;α1,4; or α1,6; and i = α, β, or a mixture of α and β] The present invention provides an oligosaccharide-protein conjugate comprising an oligosaccharide represented by the formula:

[0019] Additional embodiments of the present invention include a compound comprising: (1) a protein; and (2) a compound of formula IV:

[0020] [ka]

[0021] [In the formula, j is α1,2; k is selected from α, β, and a mixture of α and β; x is 1, 2, or 3; and When x is 2 or 3, the linkage between each mannose is selected from α1,2; α1,3; α1,4; and α1,6. The present invention provides an oligosaccharide-protein conjugate comprising an oligosaccharide represented by the formula:

[0022] Further embodiments include (1) a protein and (2) a compound of formula V:

[0023] [ka]

[0024] [In the formula, l is selected from α, β, and a mixture of α and β. The present invention provides an oligosaccharide-protein conjugate comprising an oligosaccharide represented by the formula:

[0025] Additional embodiments include a compound comprising: (1) a protein; and (2) a compound of formula VI:

[0026] [ka]

[0027] [In the formula, R x and R y each independently represents a polyethylene glycol, a C-C alkyl group optionally substituted with oxo, nitro, halo, carboxyl, cyano, or lower alkyl, and optionally interrupted by one or more heteroatoms selected from N, O, or S; 10 alkyl; z is selected from 0, 1, 2, 3, or 4; m is selected from α, β, and a mixture of α and β; When y is 2, 3, or 4, the linkage between each mannoses is selected from α1,2; α1,3; α1,4; and α1,6. The present invention provides an oligosaccharide-protein conjugate comprising an oligosaccharide represented by the formula:

[0028] In an additional embodiment, the invention provides an oligosaccharide-protein conjugate comprising: (1) a protein; and (2) an oligosaccharide represented by Formula A.

[0029] In certain embodiments, the complex comprises at least 2, 3, 4, or 5 moles of oligosaccharide of formula A per mole of protein.

[0030] In some embodiments, the oligosaccharide-protein conjugates of the invention contain a linker between the oligosaccharide and protein components of the conjugate.

[0031] The present invention provides a pharmaceutical composition comprising an oligosaccharide-protein conjugate of formula I, II, III, IV, V or VI and a filler, swelling agent, disintegrant, buffer, stabilizer or excipient. The present invention further provides a method for treating a lysosomal storage disease, e.g., as disclosed in Table 1 below, using an oligosaccharide-protein conjugate of formula I, II, III, IV, V or VI, or a pharmaceutical composition comprising an oligosaccharide-protein conjugate or the like. The lysosomal storage disease can be selected from, e.g., Fabry disease, Pompe disease, Niemann-Pick A disease, Niemann-Pick B disease, and mucopolysaccharidosis type I. In a further embodiment, the present invention provides the use of an oligosaccharide-protein conjugate comprising (1) a protein and (2) an oligosaccharide of formula I, II, III, IV, V or VI for the manufacture of a medicament for treating a lysosomal storage disease in a subject in need thereof.

[0032] Additional embodiments of the present invention are discussed throughout this application. Other objects, features, and advantages of the present invention will become apparent from the following detailed description. Any embodiment discussed with respect to one aspect of the present invention also applies to another aspect of the present invention, and vice versa. It is understood that the embodiments in the Examples section are embodiments of the present invention that can be applied to all aspects of the present invention.

[0033] It should be understood, however, that the detailed description and specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the scope and spirit of the invention will become apparent to those skilled in the art from this application. [Brief description of the drawings]

[0034] [Figure 1] FIG. 1 shows an exemplary retrosynthetic scheme illustrating the steps in the synthesis of oligosaccharide 82. [Diagram 2]FIG. 2 shows an exemplary synthesis of a monosaccharide building block 2a that can be used in the oligosaccharide synthesis described herein. [Diagram 3] FIG. 3 shows an exemplary synthesis of monosaccharide building blocks 1, 2, 3, and 4 that can be used in the oligosaccharide synthesis described herein. [Figure 4] FIG. 4 shows a synthetic scheme for the preparation of an ethylene linker. [Diagram 5] FIG. 5 shows a synthetic scheme for the construction of the trisaccharide precursor of oligosaccharide 82 using building blocks 2, 3, and 4. [Figure 6] FIG. 6 shows a synthetic scheme for the construction of a protected heptasaccharide from the trisaccharide precursor described in FIG. [Figure 7] FIG. 7 shows a synthetic scheme for deprotection of the protected heptasaccharide described in FIG. [Figure 8A] FIG. 8A shows a synthetic scheme for preparing a β-linked hexasaccharide of formula A utilizing dibutyltin to form a stereoselective intermediate and alternative form of a thiol reactive group. [Figure 8B] FIG. 8B shows a synthetic scheme for preparing a β-linked hexasaccharide of formula A utilizing dibutyltin to form a stereoselective intermediate and alternative form of a thiol reactive group. [Figure 8C] FIG. 8C shows a synthetic scheme for preparing a β-linked hexasaccharide of formula A utilizing dibutyltin to form a stereoselective intermediate and alternative form of a thiol reactive group. [Figure 8D] FIG. 8D shows a synthetic scheme for preparing a β-linked hexasaccharide of formula A utilizing dibutyltin to form a stereoselective intermediate and alternative form of a thiol reactive group. [Figure 8E] FIG. 8E shows a synthetic scheme for preparing a β-linked hexasaccharide of formula A utilizing dibutyltin to form a stereoselective intermediate and alternative form of a thiol reactive group. [Figure 9A]Figure 9 shows the effect of oxidation level on the complexation ability of NeoGAAβ SAM6. Figure 9A shows the amount of SAM2, SAM3, SAM4, linear SAM4, αSAM6, and βSAM6 oligosaccharides complexed with GAA at various molar ratios. [Figure 9B] Figure 9B shows the effect of oxidation level on the conjugation ability of NeoGAAβ SAM6, and Figure 9B shows the amount of hexasaccharide (glycan) conjugated to rhGAA oxidized with different amounts of periodate. [Figure 10A] Figure 10 shows the oxidation of sialic acid, fucose, galactose, and mannose with various amounts of periodate. Figure 10A shows the oxidation measured by analysis of monosaccharide composition (oxidation inferred based on the decrease in the amount of quantified monosaccharides). [Figure 10B] Figure 10B shows the oxidation of sialic acid, fucose, galactose, and mannose with various amounts of periodate, and Figure 10B shows LTQ MS detection of AA-labeled SAM6 oligosaccharides in positive mode. [Figure 10C] Figure 10 shows the oxidation of sialic acid, fucose, galactose, and mannose with various amounts of periodate, and Figure 10C shows the MS / MS spectra corresponding to AA-labeled oxidized oligosaccharides. [Figure 10D] Figure 10 shows the oxidation of sialic acid, fucose, galactose, and mannose with various amounts of periodate. Figure 10D shows the MS / MS spectra corresponding to AA-labeled oxidized oligosaccharides. [Figure 10E] Figure 10 shows the oxidation of sialic acid, fucose, galactose, and mannose with various amounts of periodate.Figure 10E shows the monosaccharide analysis of GAM complexes titrated with different amounts of GAO. [Figure 11A] FIG. 11A shows HPLC analysis of oligosaccharides released from rhGAA and NeoGAA. [Figure 11B] FIG. 11B shows HPLC analysis of oligosaccharides released from rhGAA and NeoGAA. [Figure 11C]FIG. 11C shows HPLC analysis of oligosaccharides released from rhGAA and NeoGAA. [Figure 12] Figure 12 shows LC / MS analysis of peptide mapping of rhGAA treated with 2 and 22.5 mM periodate. The elution positions of non-oxidized, mono-oxidized, and di-oxidized tryptic peptide T13 (containing methionines 172 and 173) are highlighted by rectangles. [Figure 13A] Figure 13 shows Biacore binding analysis of NeoGAA and rhGAA to sCIMPR.Figure 13A is a sensorgram showing the binding, dissociation, M6P elution, and regeneration steps for each sample injection. [Figure 13B] Figure 13B shows Biacore binding analysis of NeoGAA and rhGAA to sCIMPR.Figure 13B is an exemplary four parameter fit of the sensorgram data for NeoGAA and rhGAA control samples. [Figure 13C] Figure 13B shows Biacore binding analysis of NeoGAA and rhGAA to sCIMPR. Figure 13C is the M6P receptor affinity of NeoGAA samples prepared with 2mM vs. 7.5mM periodate across different binding levels of each preparation. [Figure 14] FIG. 14 shows the specific activity of various NeoGAA complexes. [Diagram 15AB] FIG. 15AB shows the elution of the NeoGAA complex from the M6P receptor column. [Figure 15C] FIG. 15C shows the elution of the NeoGAA complex from the M6P receptor column. [Figure 15D] FIG. 15D shows the elution of the NeoGAA complex from the M6P receptor column. [Figure 15E] FIG. 15E shows the elution of the NeoGAA complex from the M6P receptor column. [Figure 15F] FIG. 15F shows tissue glycogen levels in GAAKO mice after four weekly doses of SAM6 complex. [Figure 16]FIG. 16 shows the results of an uptake assay in L6 myoblasts demonstrating the uptake of various NeoGAA conjugates. [Figure 17] FIG. 17 shows glycogen clearance in heart, quadriceps, and triceps in GAA knockout mice following SAM2 treatment. [Figure 18] FIG. 18 shows cardiac and quadriceps glycogen clearance in GAA knockout mice following SAM4 treatment. [Figure 19] FIG. 19 shows cardiac and quadriceps glycogen clearance in GAA knockout mice following SAM6 treatment. [Figure 20] FIG. 20 shows cardiac and quadriceps glycogen clearance in GAA knockout mice following SAM6 and GAM6 treatment. [Figure 20B] FIG. 20B shows the concentrations of rhGAA in mouse serum collected at 5, 15, 30, 60, 120, 240, and 480 minutes after administration of rhGAA, GAM, and SAM complexes. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0035] Description of the Invention In order to better understand the present invention, certain terms are first defined. Additional definitions are provided throughout this application.

[0036] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, a reference to a method including "a compound" includes a mixture of two or more compounds. The word "or" is generally used in its sense including "and / or" unless the context clearly dictates otherwise.

[0037] I. Oligosaccharide-Protein Complexes In one embodiment, the invention provides an oligosaccharide-protein conjugate, which may further comprise a linker. Exemplary oligosaccharides, proteins, linkers, conjugation methods, and conjugates are disclosed.

[0038] A. Oligosaccharides The oligosaccharides can be selected from biantennary oligosaccharide derivatives of formula B or formula VI as shown above, or linear oligosaccharide derivatives as shown in formulas IV and V. Generally, biantennary oligosaccharides have two M6P residues at the terminals, and in some embodiments can further include one or more penultimate M6P residues. Linear oligosaccharides have at least one M6P residue and may include terminal M6P residues. Generally, the terminal M6P residues may be linked by α1,2 linkages (see Distler et al., J. Biol. Chem. 266:21687-21692 (1991) who observed that terminal M6P α1,2 linkages bind more to the CI-MPR and cation-dependent MPR (CD-MPR) than α1,3 or α1,6 linkages). In some embodiments, the terminal M6P residues are linked to adjacent residues at each reducing end by α1,2 bonds. In some embodiments, the two terminal M6P residues are separated by more than 5, 10, 15, 20, 25, 30, 35, or 40 Å, e.g., as determined by X-ray crystallography, NMR, and / or molecular modeling. For example, molecular modeling can be performed as described in Balaji et al., Glycobiology 4:497-515 (1994). In some embodiments, oligosaccharides are selected such that the terminal M6P residues are relatively unhindered. In some embodiments, oligosaccharides with relatively unhindered terminal M6P residues bind CI-MPR with higher affinity than oligosaccharides with hindered terminal M6P residues.

[0039] In general, oligosaccharides bind to the CI-MPR. For example, oligosaccharides can bind to the CI-MPR with a dissociation constant of, for example, less than 500, 100, 50, 10, 5, 1, or 0.1 nM, or, for example, less than 100, 50, 10, 5, 2, or 1 μM. The crystal structures of the N-terminal regions 1-3 of the CI-MPR are known, both in ligand-bound and unliganded forms (Olson et al., J. Biol. Chem. 279:34000-34009 (2004); Olson et al., EMBO J. 23:2019-2028 (2004)). In addition, structurally related CD-MPRs are also known in ligand-bound and unliganded forms (Olson et al., J. Biol. Chem. 274:29889-29886 (1999); Olson et al., J. Biol. Chem. 277:10156-10161 (2002)). Thus, one skilled in the art can use the receptor structure information to select appropriate oligosaccharides.

[0040] The oligosaccharide may be selected from any one of the oligosaccharides represented by formula I, II, III, IV, V, or VI shown above, including, for example, oligosaccharides 1-127 shown below. The oligosaccharides represented by formula I-III are derived in a conventional manner from formula B by removal of branches, removal and / or replacement of monosaccharide residues, and / or modification of the linkages between adjacent monosaccharide residues (such as α1,2, α1,3, α1,4, or α1,6). In certain embodiments, the oligosaccharide may have, for example, one, two, or three additional mannose residues in one or both branches linked by α1,2, α1,3, or α1,6 linkages with respect to any one of formula I-VI.

[0041] An oligosaccharide may have, for example, one, two or three M6P residues. An oligosaccharide may have a total of one, two, three, four, five, six, seven, eight, nine or ten monosaccharide residues. In other embodiments, an oligosaccharide may have one, two, three, four, five, six, seven, eight, nine or ten mannose residues, any of which may be phosphorylated or non-phosphorylated.

[0042] In some embodiments, the oligosaccharide is selected from oligosaccharides 1-96, which are of the type of Formula I.

[0043] [ka]

[0044] [Table 1]

[0045] [Table 2]

[0046] [Table 3]

[0047] In some embodiments, d is a mixture of α and β (ie, the oligosaccharide is a mixture of, for example, oligosaccharides 1 and 2, 3 and 4, or 95 and 96).

[0048] In some embodiments, the oligosaccharide is selected from oligosaccharides 97-103, which are of formula II.

[0049] [ka]

[0050] In some embodiments, f is a mixture of α and β (ie, the oligosaccharide is, for example, a mixture of oligosaccharides 97 and 98, 99 and 100, or 101 and 102).

[0051] In some embodiments, the oligosaccharide is selected from oligosaccharides 104-127, which are of formula III.

[0052] [ka]

[0053] In some embodiments, i is a mixture of α and β (ie, the oligosaccharide is, for example, a mixture of oligosaccharides 104 and 105, 106 and 107, or 126 and 127).

[0054] In some embodiments, the oligosaccharide is selected from oligosaccharides 128-133, which are of formula IV.

[0055] [ka]

[0056] In some embodiments, k is a mixture of α and β (ie, the oligosaccharide is, for example, a mixture of oligosaccharides 128 and 129, 130 and 131, or 132 and 133).

[0057] In some embodiments, the oligosaccharide is selected from oligosaccharides 134 and 135, which are of formula V type.

[0058] [ka]

[0059] In some embodiments, the oligosaccharides are a mixture of oligosaccharides 134 and 135.

[0060] In some embodiments, the oligosaccharide is oligosaccharide 136, which is of formula VI.

[0061] [ka]

[0062] In some embodiments, the oligosaccharides can be isolated from a natural source. The oligosaccharides isolated from a natural source can be a homogeneous mixture or a heterogeneous mixture of related oligosaccharides.

[0063] In certain embodiments, oligosaccharides are produced by chemical and / or enzymatic synthesis, hi some embodiments, oligosaccharides can be produced by chemical or enzymatic modification of oligosaccharides isolated from natural sources ("semi-synthetic").

[0064] Oligosaccharides are described in, for example, Figures 1 to 7, Obsorn et al., Oligosaccharides: Their Synthesis and Biological Roles, Oxford University Press, 2000, Wang et al. (eds), Synthesis of Carbohydrates through Biotechnology, American Chemical Society, 2004, Seeberger, Solid Support Oligosaccharide Synthesis and Combinatorial Carbohydrate Libraries, Wiley-Interscience, 2001, Driguez et al., Glycoscience: Synthesis of Oligosaccharides and Glycoconjugates, Springer, 1999, Duffels et al., Chem. Eur. J. 6: 1416-1430 (2000), Hojo et al., Current Prot. Peptide Sci. 1: 23-48 (2000), Seeberger et al., Nature 446: 1046-1051 (2007), Seeberger et al., Nature Rev. Drug Discov. 4:751-763 (2005), Srivastana et al., Carbohydrate Res. 161:195-210 (1987), and Hagihara et al., Chem. Rec. 6:290-302 (2006), and U.S. Pat. Nos. 5,324,663, 6,156,547, 6,573,337, 6,723,843, 7,019,131, and 7,160,517.

[0065] In some embodiments, oligosaccharides can be synthesized by sequentially adding monosaccharides. In certain embodiments, monosaccharides can be added to specific positions (e.g., 2-O, 3-O, 4-O, or 6-O) of existing sugars by selective protection and deprotection. For example, oligosaccharide 82 can be synthesized as described in the retrosynthetic analysis of FIG. 1 and the synthetic schemes depicted in FIGS. 2-7. In some embodiments, building block 2a can be substituted for building block 2 in the synthetic schemes of FIGS. 3, 5, and 6. If building block 2a is used at the heptasaccharide stage, removal of the benzylidene group of building block 2 can be avoided.

[0066] Mannose residues can be enzymatically phosphorylated, e.g., as described in U.S. Patent No. 6,905,856. In certain embodiments, one, two, or three M6P residues can be replaced with hydrolase-resistant M6P mimetics, e.g., malonyl ethers, malonic acids, and phosphates, as described in Berkowitz et al., Org. Lett. 6:4921-4924 (2004).

[0067] In certain embodiments, the linker can be attached to the sugar via an α or β bond. In some embodiments, the β bond can be formed by the methods described in Crich et al., Tetrahedron, 54:8321-8348 (1998); Kim et al., J. Am. Chem. Soc., 130:8537-8547 (2008); Srivasta et al., Tetrahedron Letters, 35:3269-3272 (1979); Hodosi et al., J. Am. Chem. Soc., 119:2335-2336 (1997); Nicolaou et al., J. Am. Chem. Soc., 119:9057-9058 (1997). In one embodiment, the β bond can be formed using dibutyltin oxide to form an intermediate that can be reacted with a linker that contains an inert leaving group.

[0068] One embodiment is of formula VII:

[0069] [ka]

[0070] [In the formula, R1 is selected from hydrogen, hydroxyl, optionally substituted lower alkyl, phosphate, sulfate, -OR7, a protecting group, and a sugar; R2, R3, R4 and R5 are each independently selected from hydrogen, sulfate, hydroxyl, -OR8, a protecting group, and a sugar; R6 is selected from hydrogen, hydroxyl, carboxyl, alkoxycarbonyl, amino, amido, alkyamino, aminoalkyl, aminoxy, hydrazide, hydrazine, optionally substituted alkenyl, and optionally substituted C2-C6 alkyl; R7 and R8 are each independently selected from acetyl and optionally substituted lower alkyl; and n is an integer from 1 to 10. A method for producing a compound represented by the following steps: a) Formula VIII:

[0071] [ka]

[0072] [In the formula, R1 to R5 are as defined above; and R9 and R 10 R9 and R 10 is selected from hydrogen and hydroxyl, such that when one of is hydroxyl, the other is hydrogen. The compound represented by the formula R 11 R 12 (Sn=O) to give a compound of formula IX:

[0073] [ka]

[0074] [In the formula, R1 to R5 are as defined above; and R 11 and R 12 are each independently selected from unsubstituted alkyl, or R 11 and R 12 taken together are selected from unsubstituted alkylene. To form a compound represented by the formula: b) reacting a compound of formula IX with a compound of formula R6-(CH2) optionally in the presence of a metal halide n -L: [In the formula, R6 and n are as defined above; and L is a halogen. with a compound of formula VII to form a compound of formula VII The method includes:

[0075] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the specification includes examples where the event or circumstance occurs and examples where it does not occur. For example, "optionally substituted alkyl" includes both "alkyl" and "substituted alkyl" as defined below. It will be understood by those of skill in the art that with respect to any group that contains one or more substituents, it is not intended that such groups incorporate any substitution or forms of substitution that are sterically impractical, synthetically impractical, and / or inherently unstable.

[0076] "Alkyl" includes straight and branched chains having a specified number of carbon atoms, typically having 1-20 carbon atoms, such as having 1-8 carbon atoms, for example having 1-6 carbon atoms. For example, C1-C6 alkyl includes both straight and branched chain alkyls of 1-6 carbon atoms. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 3-methylpentyl, and the like. Alkylene is another collection of alkyl, representing the same residue as alkyl, but with two points of attachment. Alkylene groups typically have 2-20 carbon atoms, typically having 2-8 carbon atoms, for example having 2-6 carbon atoms. For example, C0 alkylene indicates one covalent bond, and C1 alkylene is a methylene group. When an alkyl residue having a specific number of carbons is specified, all geometric isomers having that number of carbons are intended to be included. Thus, for example, "butyl" is meant to include n-butyl, sec-butyl, isobutyl, and t-butyl, and "propyl" includes n-propyl and isopropyl. "Lower alkyl" refers to alkyl groups having 1 to 4 carbons.

[0077] "Alkenyl" refers to an unsaturated branched or straight chain alkyl group having at least one carbon-carbon double bond formed by the removal of one hydrogen molecule from adjacent carbon atoms of a parent alkyl. The double bond may be in either the cis or trans configuration. Exemplary alkyl groups include, but are not limited to, ethenyl; propenyl, such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl; butenyl, such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, and the like. In some embodiments, alkenyl groups have from 2 to 20 carbon atoms, and in other embodiments, from 2 to 6 carbon atoms.

[0078] The term "substituted" as used herein means that one or more hydrogens of the designated atom or group are replaced with one selected from the indicated group, but not exceeding the normal valence of the designated atom. When the substituent is oxo (i.e., =O), two hydrogens of the atom are replaced. Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates. A stable compound or stable structure is indicative of a compound that is sufficiently robust to survive isolation from a reaction mixture and subsequent formulation as a pharmaceutical having at least practical utility. Unless otherwise noted, the substituents are named on the core structure. For example, when (cycloalkyl)alkyl is listed as a possible substituent, it should be understood that the attachment point of this substituent to the core structure is on the alkyl moiety.

[0079] Unless expressly defined otherwise, the term "substituted alkyl" refers to an alkyl in which one or more hydrogen atoms are replaced by a substituent independently selected from the following: -R a , -ORb , -O(C1-C2 alkyl)O- (e.g., methylenedioxy-), -SR b , -NR b R c , halo, cyano, oxo, nitro, sulfate, phosphate, -COR b , -CO2R b , -CONR b R c , -OCOR b , -OCO2R a , -OCONR b R c , -NR c COR b , -NR c CO2R a , -NR c CONR b R c , -SOR a , -SO2R a , -SO2NR b R c , -NR c SO2R a , ethylene glycol, and polyethylene glycol (PEG). Here, R a is selected from optionally substituted C1-C6 alkyl, optionally substituted aryl, and optionally substituted heteroaryl; R b is hydrogen, -NH2, -NHR c , optionally substituted C1-C6 alkyl, optionally substituted aryl, and optionally substituted heteroaryl; R c is selected from hydrogen and optionally substituted C1-C4 alkyl; or R b and R c and the nitrogen atom to which they are attached form an optionally substituted heterocycloalkyl group; and Each optionally substituted group may be unsubstituted or may be selected from the group consisting of C1-C4 alkyl, aryl, heteroaryl, aryl-C1-C4 alkyl-, heteroaryl-C1-C4 alkyl-, C1-C4 haloalkyl-, -OC1-C4 alkyl, -OC1-C4 alkylphenyl, -C1-C4 alkyl-OH, -OC1-C4 haloalkyl, halo, -OH, -NH2, -C1-C4 alkyl-NH2, -N(C1-C4 alkyl)(C1-C4 alkyl), -NH(C1-C4 alkyl), -N(C1-C4 alkyl)(C1-C4 alkylphenyl), -NH(C1-C4 alkylphenyl), cyano, nitro, oxo (as a heteroaryl substituent), -CO2H, -C(O)OC1-C4 alkyl, -CON(C1-C4 alkyl)(C1-C4 alkyl), - and may be independently substituted with one or more substituents independently selected from CONH(C1-C4 alkyl), -CONH2, -NHC(O)(C1-C4 alkyl), -NHC(O)(phenyl), -N(C1-C4 alkyl)C(O)(C1-C4 alkyl), -N(C1-C4 alkyl)C(O)(phenyl), -C(O)C1-C4 alkyl, -C(O)C1-C4 phenyl, -C(O)C1-C4 haloalkyl, -OC(O)C1-C4 alkyl, -SO2(C1-C4 alkyl), -SO2(phenyl), -SO2(C1-C4 haloalkyl), -SON2NH2, -SON2NH(C1-C4 alkyl), -SON2NH(phenyl), -NHSO2(C1-C4 alkyl), -NHSO2(phenyl), and -NHSO2(C1-C4 haloalkyl).

[0080] In some embodiments, R1 is selected from hydrogen, optionally substituted lower alkyl, phosphate, sulfate, -OR7, a protecting group, and a sugar. In additional embodiments, R2, R3, R4, and R5 are each independently selected from hydrogen, sulfate, hydroxyl, -OR8, a protecting group, and a sugar. In certain embodiments, R7 and R8 are each independently selected from acetyl and optionally substituted lower alkyl. In some embodiments, any or all of R1, R2, R3, R4, and R5 can be selected from selectively removable protecting groups, including benzyl, silyl, and trityl ethers, and esters other than acetate. In some embodiments, two of R1 through R5 together form a protecting group. In one embodiment, R1 is selected from -O-benzyl and -OCPh3. In another embodiment, at least one of R2 through R5 is -O-benzyl. In some embodiments, R1, R2, and R4 are each -O-benzyl. In a further embodiment, R1 is -OCPh3 and R4 is -O-benzyl. 11 and R 12 taken together form hexamethylene. In another embodiment, R 11 and R 12 and R are each isopropyl. 11 and R 12 are hexyl, respectively.

[0081] In additional embodiments, the compound of formula VIII is selected from optionally protected mannose, rhamnose, idose, and altrose. In one embodiment, the compound of formula VIII is an optionally protected mannose. In some circumstances, mannose may be protected at one or more of the C-3, C-4, or C-6 positions. In some instances, a single protecting group can be attached to two positions. For example, a benzylidene group can be used to protect both the C-4 and C-6 positions.

[0082] In general, any protecting group for the compound of formula IX and the sugar that is not strongly electrophilic or cross-reactive can be used. Suitable protecting groups include ethers, such as optionally substituted benzyl ether, trityl ether, allyl ether, or silyl ether; esters, such as optionally substituted acetate, benzoic acid, chloroacetate, pivalic acid, or levulinic acid; acetals, including benzylidene, isopropylidene, and butane diacetal, and the like. Additionally, the protecting group can be selected from carbamates and urethanes. In some embodiments, protecting groups, such as benzyl, silyl, and trityl ethers, and esters other than acetate, can be selectively removed. The location and identity of the protecting group can be varied depending on the desired end product. Additional protecting groups known to those skilled in the art can be used in accordance with the embodiments described herein.

[0083] In one embodiment, the compound of formula VIII has the formula R 11 R 12 (Sn=O) and the compound represented by the formula R 11 and R 12 are each independently selected from unsubstituted alkyl, or R 11 and R 12 and taken together are selected from unsubstituted alkylene. 11 and R 12 is butyl. In one embodiment, the formula R 11 R 12 A compound represented by (Sn=O) is reacted with a compound of formula VIII in a solvent such as toluene, benzene, dimethylformamide, isopropanol, methanol, or xylene. In some embodiments, the reaction is carried out at elevated temperature, optionally under reflux, to form a compound of formula IX. In some embodiments, the reaction mixture is heated to at least 40, 50, 60, 70, or 80° C. In additional embodiments, a compound of formula R 11 R 12 The compound represented by (Sn=O) is reacted with the compound of formula VIII for at least 1, 2, 5, 10, 15, or 20 hours.

[0084] In one embodiment, the compound of formula IX is treated with a compound of formula R6-(CH2)-L, optionally in the presence of a metal halide. In some embodiments, R6 is selected from hydrogen, hydroxyl, carboxyl, alkoxycarbonyl, amino, amido, alkyamino, aminoalkyl, aminoxy, hydrazide, hydrazine, optionally substituted alkenyl, and optionally substituted C2-C6 alkyl. In additional embodiments, n is an integer from 1 to 10. In certain embodiments, n is 2, 3, 4, 5, or 6, and R6 is C1-C4 alkoxycarbonyl. In one embodiment, n is 3, and R6 is methoxycarbonyl. In some embodiments, L is a leaving group that is not activated. Examples of activated leaving groups include triflates, sulfonates, tosylates, and other similar groups. In some embodiments, a leaving group with low reactivity can be activated by an adjacent group, such as an allyl group. In certain embodiments, R6 does not contain a substituent that activates the leaving group. In some embodiments, L is bromide, chloride, or iodide. In one embodiment, L is bromide. In an additional embodiment, the formula R6-(CH2) n The compound -L is methyl 4-bromobutyrate.

[0085] In one embodiment, the compound of formula VIII is an optionally protected mannose and has the formula R6-(CH2) n In another embodiment, the compound of formula VIII is selected from 3,4,6-tri-O-benzyl-D-mannose and 3-O-allyl-6-O-trityl-D-mannose.

[0086] In some embodiments, the compound of formula IX is represented by the formula R6-(CH2) nIn some embodiments, the compound of formula IX is treated with a compound of formula R6-(CH2) in the presence of a metal halide. Certain embodiments of the metal halide include a metal fluoride. In some embodiments, the metal fluoride is selected from cesium fluoride, sodium fluoride, calcium fluoride, magnesium fluoride, lithium fluoride, and potassium fluoride. In one embodiment, the metal halide is cesium fluoride. In some embodiments, the compound of formula IX is treated with a compound of formula R6-(CH2) n Treating with the compound of -L further comprises the addition of a tetraalkylammonium halide. In some examples, the tetraalkylammonium halide is tetrabutylammonium iodide. In additional embodiments, a metal halide can be used in the reaction. Examples of metal halides include alkali metal iodides such as sodium iodide.

[0087] In one embodiment, the compound of formula IX is reacted with a compound of formula R6-(CH2) in a polar aprotic solvent. n -L. Such solvents include dimethylformamide, dimethylacetamide, dimethylsulfoxide, nitromethane, hexamethylphosphoramide, N-methylpyrrolidone, acetone, acetonitrile, ethyl acetate, and methyl ethyl ketone, among others known to those skilled in the art.

[0088] In certain embodiments, the compound of formula IX has the formula R6-(CH2) n -L at room temperature. In other embodiments, the reactants are combined and heated to at least 50, 60, 70, or 80° C. to form a compound of formula VII. In further embodiments, the mixture is heated for at least 1, 2, 5, 10, 15, or 20 hours.

[0089] In some embodiments, the methods described herein result in at least 50, 60, 70, 80, 90, 95, or 99% stereospecific product. In additional embodiments, the yield of stereospecific product is at least 50, 60, 70, 75, 80, 85, 90, 95, or 99% of the maximum possible yield. In certain embodiments, the ratio of β-linked product to α-linked product is at least 10:1, 20:1, 30:1, 40:1, 50:1, or 100:1.

[0090] In one embodiment, the compound of formula VII can be produced on a large scale. In some embodiments, "large scale" refers to using at least 50, 100, 500, or 1000 grams of starting material, intermediate, or reagent. In additional embodiments, "large scale" includes using at least 10, 25, 50, 100, 250, or 500 kg of starting material, intermediate, or reagent.

[0091] An exemplary synthetic scheme for preparing compounds of formula A using dibutyltin oxide reagent is shown in FIG.

[0092] B. Protein The oligosaccharide-protein conjugates described herein may include any pure protein, partially purified protein, or fragments thereof, including isolated proteins, and recombinantly or synthetically produced proteins. The terms "pure," "purified," and "isolated" refer to a molecule that is substantially free of its natural environment. By way of example, a pure protein is substantially free of cellular material and / or other proteins from the cell or tissue source from which it is derived. The term refers, for example, to preparations that are at least 70-80%, 80-90%, 90-95%, or at least 95%, 96%, 97%, 98%, 99%, or 100% (w / w) pure.

[0093] In other embodiments, the protein may be an enzyme that has an optimum activity, as measured by an activity assay, in the pH range of 1-7, such as 1-3, 2-5, 3-6, 4-5, 5-6, or 4-6. For example, the enzyme may have an optimum pH in the pH range of 4-6.

[0094] In some embodiments, the protein can be an enzyme with an isoelectric point (pI) in the range of 1 to 8, such as 1 to 3, 2 to 5, 3 to 8, 4 to 5, 5 to 6, 4 to 6, 5 to 8, 6 to 8, or 7 to 8. The pI of a protein can be measured, for example, using gel isoelectric focusing.

[0095] In certain embodiments, the protein itself has at least one oligosaccharide (i.e., is a glycoprotein). In particular embodiments, the protein is a therapeutic glycoprotein. For example, the therapeutic glycoprotein may be a lysosomal enzyme, including an ERT enzyme, such as, for example, one of the lysosomal hydrolases listed in Table 1. In certain embodiments, the lysosomal enzyme is selected from, for example, α-glucosidase (GAA), α-galactosidase A, acid sphingomyelinase, and α-L-iduronidase. In particular embodiments, the lysosomal enzyme is GAA.

[0096] [Table 4]

[0097] In some embodiments, the protein can be a glycoprotein having at least one, two, three, four, five, or more N-linked or O-linked oligosaccharides, hi other embodiments, the protein can have one, two, three, four, five, or more consensus sites for N-linked or O-linked glycosylation, at least one of which is glycosylated.

[0098] In certain embodiments, the protein may be a ligand for a receptor. For example, in some embodiments, the protein may be a glycoprotein that binds to a receptor that recognizes a sugar, such as mannose or mannose-6-phosphate. In particular embodiments, the glycoprotein may bind to, for example, the asialoglycoprotein receptor, the CI-MPR, the CD-MPR, or the mannose receptor.

[0099] Suitable protein sequences are well known to those skilled in the art. Those skilled in the art can easily identify conserved regions and important functional motifs by comparing related sequences, including sequences from different species. Conserved amino acids are more likely to be important for activity, and conversely, non-conserved amino acids indicate regions of the polypeptide that are more likely to tolerate variation. Following this guideline, those skilled in the art can easily identify functional variants by mere routine. Furthermore, if a crystal structure is known, those skilled in the art can analyze the crystal structure to identify amino acids that are important for structure and / or function and therefore likely to be less tolerant of mutations. Those skilled in the art can also identify amino acids that may tolerate mutations. Furthermore, those skilled in the art can evaluate potential mutations in light of known structure-function relationships.

[0100] For example, the sequence and structure of α-galactosidase are well known. See, e.g., Garman et al., J. Mol. Biol., 337:319-335 (2004); Garman et al., Mol. Genet. Metabol., 77:3-11 (2002); Matsuzawa et al., Hum. Genet. 117:317-328 (2005). See also GenBank Accession No. X05790. In another example, the sequence of GAA is known (see, e.g., Martiniuk et al., Proc. Natl. Acad. Sci. USA 83:9641-9644 (1986); Hoefsloot et al., Biochem. J. 272:493-497 (1990); Moreland et al., J. Biol. Chem. 280:6780-6791 (2005)). See also GenBank Accession No. NM_000152. Additionally, the crystal structure of the corresponding α-glycosidase from E. coli has been determined and can provide structural insight into other α-glycosidases. See Lovering et al., J. Biol. Chem. 280:2105-2115 (2005). In a third example, the sequence of acid sphingomyelinase is well known as are key features of acid sphingomyelinase sequence and structure (see, e.g., Lansmann et al., Eur. J. Biochem. 270:1076-1088 (2003)). See, e.g., Seto et al., Protein Sci. 13:3172-3186 (2004); Qiu et al., J. Biol. Chem. 278:32744-32752 (2003); Takahashi et al., Tohoku J. Exp. Med. 206:333-340 (2005). See also GenBank Accession No. AI587087. In yet another example, the sequence of α-L-iduronidase is well known, as are key features of α-L-iduronidase (see, e.g., Scott et al., Proc. Natl. Acad. Sci USA 88:9695-9699 (1991); Scott et al., Genomics 13:1311-1313 (1992)).See, e.g., Scott et al., Hum. Mutat. 6:288-302 (1995); Rempel et al., Mol. Genet. Metab. 85:28-37 (2005); Durand et al., Glycobiology 7:277-284 (1997); Beesley et al., Hum. Genet. 109:503-511 (2001); Brooks et al., Glycobiology 11:741-750 (2001); Nieman et al., Biochemistry 42:8054-8065 (2003). In a further example, iduronate-2-sulfatase sequences are known to be disease-causing mutations. See, e.g., Flomen et al., Hum. Mol. Genet. 2:5-10 (1993); Roberts et al., J. Med. Genet. 26:309-313 (1989); Wilson et al., Proc. Natl. Acad. Sci. USA 87:8531-8535 (1990); Wilson et al., Genomics 17:773-775 (1993); Sukegwa-Hayasaka et al., J. Inherit. Metab. Dis 29:755-761 (2006) and references therein. The structure of iduronate-2-sulfatase has been modeled. See, e.g., Kim et al., Hum. Mutat. 21:193-201 (2003). In another example, the sequence and structure of N-acetylgalactosamine-4-sulfatase (arylsulfatase B) is known to be a disease-causing mutation. See, e.g., Litjens et al., Hum. Mut. 1:397-402 (1992); Peters et al., J. Biol. Chem. 265:3374-3381 (1990); Schuchman et al., Genomics 6:149-158 (1990); Bond et al., Structure 15:277-289 (1997).

[0101] C. Linker In certain embodiments, the oligosaccharide-protein conjugates of the invention include a linker between the oligosaccharide and protein components of the conjugate. In other embodiments, the conjugate does not include a linker. In embodiments that include a linker, any suitable linker known to those of skill in the art can be used, so long as it does not interfere with the binding of the oligosaccharide to the CI-MPR and / or does not interfere with the activity of the protein (including, for example, enzymatic activity). For example, the linker can be one of the linkers disclosed in U.S. Patent Nos. 4,671,958, 4,867,973, 5,691,154, 5,846,728, 6,472,506, 6,541,669, 7,141,676, 7,176,185, 7,232,805, or U.S. Patent Application Publication No. 2006 / 0228348. In some embodiments, the linker is selected from the linkers disclosed in WO 2008 / 089403.

[0102] In some embodiments, the linker can have the formula:

[0103] [ka]

[0104] [In the formula, Z is selected from optionally substituted alkyl, alkenyl, alkynyl, aryl, ethylene glycol, polyethylene glycol (PEG), heteroaryl, and heterocyclyl; and P is selected from hydrogen or an amino protecting group.

[0105] Any chemical group of the aminooxy compound used herein (e.g., alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, acyloxy, alkoxy, aryloxy, and heterocyclyloxy, etc.) may be substituted or unsubstituted and may be interrupted by one or more heteroatoms or chemical groups, unless otherwise stated. Interrupting heteroatoms include nitrogen, oxygen, and sulfur. Substituents or interrupting chemical groups may be selected from, for example, acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amido, amino, aryl, aryloxy, azido, carbamoyl, carboalkoxy, carboxy, cyano, cycloalkyl, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonato, sulfonyl, thio, thioacylamino, thioureido, and ureido. The substituents themselves may be substituted or unsubstituted and may be interrupted or terminated by one or more heteroatoms such as, for example, nitrogen, sulfur, and oxygen.

[0106] In one embodiment, the linker is:

[0107] [ka]

[0108] It can be formed by reaction with

[0109] In additional embodiments, the linker can have the formula:

[0110] [ka]

[0111] wherein Z and P are as defined above.

[0112] In another embodiment, the linker can include a disulfide bond. A disulfide linker can be used to attach the oligosaccharide to the protein backbone, for example via cysteines. In one embodiment, the linker is

[0113] [ka]

[0114] It can be formed from comprising or reacting with

[0115] In general, the linker can be of any suitable length so as to avoid steric hindrance between the oligosaccharide and protein components of the complex, and / or not interfere with the binding of the oligosaccharide to the CI-MPR and / or the activity of the protein (including, for example, enzymatic activity). For example, the linker can contain 1-100, 1-60, 5-60, 5-40, 2-50, 2-20, 5-10, or 5-20 linear atoms that are attached to the protein and oligosaccharide by ester, amide, hydrazone, oxime, semicarbazone, ether, thioether, phosphorothioate, phosphonate, thioester, and / or disulfide bonds. The remaining linear atoms of the linker can be selected from, for example, carbon, oxygen, nitrogen, and sulfur, any of which may optionally be contained in a carbocyclic, heterocyclic, aryl, or heteroaryl ring. The linear carbon atoms of the linker may be optionally substituted with a substituent selected from halo, hydroxy, nitro, haloalkyl, alkyl, alkaryl, aryl, aralkyl, alkoxy, aryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, alkoxycarbonyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, alkylsulfonamido, alkylcarbonyl, acyloxy, cyano, and ureido. The linear nitrogen atoms of the linker may be optionally substituted with acyl, sulfonyl, alkyl, alkaryl, aryl, aralkyl, alkoxycarbonyl. The linear sulfur atoms of the linker may be optionally oxidized.

[0116] In certain embodiments, the linker can be cleaved, for example, as disclosed in U.S. Patent Application Publication No. 2006 / 0228348 and U.S. Patent Nos. 4,867,973, 7,176,185, and 7,232,805. In some embodiments, the linker can be cleaved under lysosomal conditions.

[0117] D. Methods for Producing Oligosaccharide-Protein Conjugates The conjugates of the invention, such as those containing an oligosaccharide of formula I, II, III, IV, V, or VI, can be prepared by any method known to those skilled in the art. In any of these methods, a suitable linker can be present in either the oligosaccharide or the protein, or both the oligosaccharide and the protein. For example, the conjugates can be prepared as described, for example, in Zhu et al., Biochem. J. 389:619-628 (2005), Zhu et al., J. Biol. Chem. 279:50336-50341 (2004), U.S. Patent Nos. 5,153,312, 5,212,298, 5,280,113, 5,306,492, 5,521,290, 7,001,994, U.S. Provisional Patent Application No. 60 / 885,457, or 60 / 885,471.

[0118] In certain embodiments, oligosaccharides can be attached to amino acids of proteins, such as cysteine ​​or lysine. For example, sugars can be attached through lysines by modifying lysine residues of proteins with succinimidyl 4-formylbenzoate. Additionally, sugars can be attached through lysines by modifying the lysines with Traut's reagent or with linkers containing disulfides, such as N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), or protected thiols, such as N-succinimidyl-S-acetylthioacetate (SATA).

[0119] In additional embodiments, oligosaccharides can be attached to glycans of glycoproteins. In one embodiment, oligosaccharides can be attached to sialic acid residues of glycans. In other embodiments, oligosaccharides can be attached to mannose, fucose, galactose, and / or sialic acid residues of glycans. For attachment via galactose, glycoproteins can first be treated with sialidase to remove sialic acid residues, and then treated with galactose oxidase before reacting with oligosaccharides.

[0120] For example, oligosaccharide-protein conjugates can be prepared by reacting any functional group that can be present in and / or introduced into a protein (including, for example, amines, thiols, carboxylic acids, hydroxyls) with a suitable second functional group on the oligosaccharide. Methods for introducing functional groups are well known in the art. For example, glycoproteins having at least one carbonyl group can be obtained by oxidizing the glycoprotein with, for example, periodate (e.g., sodium periodate) or galactose oxidase. In another example, carbonyl groups can be introduced using an expression system with an extended genetic code, as described, for example, in Wang et al., Proc. Natl. Acad. Sci. USA 100:56-61 (2003). See, for example, U.S. Patent Application Publication No. 2006 / 0228348, which describes the introduction of reactive groups into glycoproteins.

[0121] In some embodiments, the glycoprotein is oxidized with periodate prior to conjugation with an oligosaccharide modified with a linker containing a carbonyl-reactive group. Examples of carbonyl-reactive groups include aminooxy, hydrazine, or hydrazide. In certain embodiments, the glycoprotein is oxidized with about 1, 2, 3, 4, 5, 7.5, 10, or 22.5 mM periodate. In certain embodiments, the glycoprotein is oxidized under conditions sufficient to oxidize sialic acid residues of the glycoprotein glycan and minimize oxidation of fucose and mannose. In exemplary embodiments, the concentration of periodate is less than about 2, 3, 4, or 5 mM. In one embodiment, the periodate is sodium periodate.

[0122] In certain embodiments, protein aggregates formed during binding can be removed using various chromatographic methods. In one embodiment, hydrophobic interaction chromatography (HIC) can be used. Examples of HIC columns include Butyl 650C and 650M, Hexyl 650C, Phenyl 6FF, Capto Octyl, and Capto Phenyl. In other embodiments, aggregates can be removed by metal chelate chromatography, such as copper, nickel, cobalt, or mercury. In one embodiment, a copper column can be used in bind-and-elute or flow-through mode. Exemplary elution buffers include glycine or imidazole. In some embodiments, aggregates are reduced by 10, 20, 30, 40, 50, 60, 70, 80, or 90%. In additional embodiments, the complex contains less than 0.5, 1, 1.5, 2, 2.5, or 3% aggregates.

[0123] E. Complex The oligosaccharide and protein components of the complex can be, for example, any of the oligosaccharides and proteins described herein. In certain embodiments, the oligosaccharide-protein complex is an oligosaccharide-glycoprotein complex. In some embodiments, the oligosaccharide-protein complex is an oligosaccharide-lysosomal enzyme complex.

[0124] In some embodiments, the conjugate comprises an oligosaccharide selected from the oligosaccharides of formulas I-VI. In certain embodiments, the conjugate comprises an average of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 1-2, 1-3, 1-4, 1-6, 2-4, 2-10, 2-12, 4-6, 3-8, 5-6, 5-10, 5-15, 5-20, 10-15, 10-20, 12-15, 12-18, or 15-20 oligosaccharide molecules per glycoprotein. In some embodiments, the conjugate comprises at least 4, 5, 6, 7, 8, 9, or 10 oligosaccharide molecules per protein molecule. In additional embodiments, the complex comprises at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 moles of M6P per mole of protein.

[0125] In certain embodiments, the complex exhibits full activity (such as enzymatic activity) compared to the uncomplexed protein. In other embodiments, the complex may exhibit at least, for example, 50, 60, 70, 75, 80, 85, 90, 92, 94, 95, 96, 97, 98, or 99% activity compared to the uncomplexed protein. Assays for measuring activity, including enzymatic activity, are well known in the art. See, for example, Eisenthal et al., Enzyme Assays: A Practical Approach, Oxford University Press: New York, 2002. Assays for measuring the activity of lysosomal enzymes are described, for example, in Li et al., Clin. Chem. 50:1785-1796 (2004); Civallero et al., Clin Chim. Acta 372:98-102 (2006). An exemplary assay for measuring the activity of GAA is described in Example 6. See also van Diggelen et al., J. Inherit. Metab. Dis. 28:733-741 (2005) (describing an assay for acid sphingomyelinase activity), Downing et al., Plant Biotechnol. 4:169-181 (2006) (describing an assay for α-L-iduronidase activity), Voznyi et al., J. Inherit. Metab. Dis. 24:675-80 (2001) (describing an assay for iduronate-2-sulfatase activity), Murray et al., Mol. Genet. Metab. 90:307-312 (2007) (describing an assay for α-galactosidase A activity), and Brooks et al., J. Inherit. Metab. Dis. 14:5-12 (1991) (describing an assay for N-acetylgalactosamine-4-sulfatase activity).

[0126] In certain embodiments, the complex is taken up more efficiently by the target cell (e.g., endocytosis via the CI-MPR) than the corresponding uncomplexed protein. For example, the complex may be taken up more efficiently, e.g., at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 93%, 95%, 96%, 97%, 98%, 99%, 100%, 110%, 120%, 130%, 140%, 150%, or 200% (mol / mol) more efficiently in a given period of time than the uncomplexed protein. In other embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, or 1000 times (mol / mol) of the complex may be taken up by the cell type of interest (e.g., L6 myoblasts or human Pompe fibroblasts (NIGMS Human Genetic Cell Repository, Cat. No. GM20005)) compared to the unconjugated protein in a given period of time. The reference period may be, for example, 10 minutes, 30 minutes, 45 minutes, or 1, 2, 3, 5, 6, 12, 24, 48, or 72 hours or more. In vitro uptake of L6 myoblasts may be measured, for example, as described in Example 6 and Zhu et al., J. Biol. Chem. 279:50336-50341 (2004).

[0127] In certain embodiments, the complex exhibits increased binding to the CI-MPR compared to the uncomplexed protein. For example, the complexed protein may exhibit at least 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 1,000, or 10,000-fold improved affinity to the CI-MPR compared to the uncomplexed protein, e.g., as measured by comparing the association or dissociation constants of the complexed and uncomplexed proteins. Binding to the CI-MPR can be measured, for example, as described in Example 5 and in Zhu et al., J. Biol. Chem. 279:50336-50341 (2004).

[0128] In certain embodiments, the complex does not show increased uptake by the mannose receptor compared to the uncomplexed protein. Alternatively, the uptake by the mannose receptor is less than 5, 10, 15, 20, 30, 40, or 50% compared to the uncomplexed protein. Uptake by the mannose receptor of rat alveolar macrophage cells can be measured in vitro, for example, as described in Zhu et al., Biochem. J. 389:619-628 (2005).

[0129] In certain embodiments, the complex may exhibit, for example, at least a 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, or 1000-fold reduction in accumulated substrate levels of a metabolically deficient enzyme in a suitable animal model. For example, the reduction in glycogen levels in a mouse model of Pompe disease can be measured, for example, as described in Zhu et al., J. Biol. Chem. 279:50336-50341 (2004). Alternatively, a quail model of Pompe disease can be used, for example, as described in Kikuchi et al., J. Clin. Invest. 101:827-33 (1998). As another example, the reduction in accumulated glycosaminoglycans in the liver and spleen can be measured in a feline model of mucopolysaccharidosis type I, as described in Kakkis et al., Mol. Genet. Metab. 72:199-208 (2001). Additionally, reduced globotriaosylceramide levels can be measured in mouse models of Fabry disease, e.g., as described in Ioannou et al., Am. J. Hum. Genet. 68:14-25 (2001). In yet another example, reduced sphingomyelin levels can be measured in mouse models of Niemann-Pick disease types A and B, e.g., as described in Horinouchi et al., Nat. Genet. 10:288-293 (1995).

[0130] II. Pharmaceutical Compositions In some embodiments, the present invention provides use of an oligosaccharide-protein conjugate comprising (1) a protein and (2) an oligosaccharide of any one of Formulas I-VI in the manufacture of a medicament for treating a lysosomal storage disease in a subject in need thereof.

[0131] The pharmaceutical compositions described herein comprise an oligosaccharide-protein conjugate as described above and at least one additive, such as a filler, swelling agent, disintegrant, buffer, stabilizer, or excipient, etc. In some embodiments, the pharmaceutical compositions of the present invention comprise a conjugate comprising an oligosaccharide of any one of Formulas I-VI and a lysosomal enzyme.

[0132] Standard pharmaceutical formulation techniques are well known to those skilled in the art (see, for example, 2005 Physician's Desk Reference®, Thomson Healthcare: Montvale, NJ, 2004; Remington: The Science and Practice of Pharmacy, 20th ed., Gennado et al., Eds. Lippincott Williams & Wilkins: Philadelphia, PA, 2000). Suitable pharmaceutical excipients include, for example, mannitol, starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, lime, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, and the like. The composition may also include a pH buffering agent, and a wetting or emulsifying agent. The composition may or may not include a preservative.

[0133] In some embodiments, the pharmaceutical composition comprising the α-galactosidase A complex can include one or more excipients, such as, for example, mannitol, monobasic sodium phosphate monohydrate, and / or disodium hydrogen phosphate heptahydrate. In some embodiments, the pharmaceutical composition comprising the α-glucosidase complex can include one or more of mannitol, polysorbate 80, disodium hydrogen phosphate heptahydrate, and monobasic sodium phosphate monohydrate. In another embodiment, the pharmaceutical composition comprising the α-glucosidase complex can include 10 mM histidine pH 6.5 with up to 2% glycine, up to 2% mannitol, and up to 0.01% polysorbate 80.

[0134] A pharmaceutical composition can include any of the conjugates described herein as the sole active compound or in combination with other compounds, compositions, or biological agents. For example, a pharmaceutical composition can also include one or more small molecules useful for treating LSD and / or side effects associated with LSD. In some embodiments, the composition can include miglustat, and / or one or more compounds described, for example, in U.S. Patent Application Publication Nos. 2003 / 0050299, 2003 / 0153768, 2005 / 0222244, or 2005 / 0267094. In some embodiments, a pharmaceutical composition can also include one or more immunosuppressants.

[0135] The formulation of the pharmaceutical composition may vary depending on the intended mode of administration and other factors (see, e.g., Rowe et al., Handbook of Pharmaceutical Excipients, 4th ed., APhA Publications, 2003). In some embodiments, the composition may be a sterile, non-pyrogenic, off-white, lyophilized solid or powder, upon reconstitution with sterile water for injection (USP), for administration via intravenous injection. In other embodiments, the composition may be a sterile, non-pyrogenic solution.

[0136] Administration of the pharmaceutical compositions described herein is not limited to any particular delivery system, and can include, but is not limited to, parenteral (including subcutaneous, intravenous, intracranial, intramedullary, intraarticular, intramuscular, intrathecal, or intraperitoneal injection), transdermal, or oral (e.g., capsules, suspensions, or tablets). An individual can be administered a single dose or multiple doses, any of a variety of physiologically acceptable salt forms, and / or as part of a pharmaceutical composition, along with acceptable pharmaceutical carriers and / or excipients.

[0137] Pharmaceutically acceptable salts include, for example, acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, calcium phosphate ... edetate anion, camsylate anion, carbonate anion, chloride anion, citrate anion, dihydrochloric acid, edetate anion, edisylate anion, estolate anion, esylate anion, fumarate anion, gluceptic acid anion, gluconate anion, glutamate anion, glycollylarsanilate, hexylresorcinate anion, hydrabamine, hydrogen bromide, hydrochloric acid, hydroxynaphthoate anion, iodide anion, isethionate anion, lactate anion, lactobionic acid anion, malate anion, maleate anion, mandelate anion, The cations include mesylate, methyl bromide, methyl nitrate, methyl sulfate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate / diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, and theoclate / triethiodide; the organic cations benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, and procaine; and the metallic cations aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc. Pharmaceutically acceptable salts also include, for example, those described in Berge et al., J.Pharm.Sci.66:1-19 (1977).

[0138] The conjugates described herein are administered in a therapeutically effective amount. In general, the therapeutically effective amount may vary depending on the age, general condition, and sex of the subject, as well as the severity of the subject's condition. The dosage is determined by the physician and can be adjusted, if necessary, to suit the actual effect of the treatment. The toxicity and therapeutic effect of the compound can be determined in vitro and / or in vivo by standard pharmaceutical procedures. The dose ratio of the toxic and therapeutic effects is the therapeutic index (or therapeutic ratio), and the ratio LD 50 / ED 50 LD can be expressed as 50 is the lethal dose for 50% of all individuals, and ED 50 is the dose that is therapeutically effective in 50% of all individuals. Conjugates of the invention may, for example, exhibit therapeutic indices of at least 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 20.

[0139] The data obtained from in vitro assays and animal studies can be used, for example, to determine a range of dosages in humans. The dosage of the compound is preferably administered at a dose that is sufficient to induce ED with little, little, or no toxicity. 50 The therapeutically effective amount of any conjugate can be estimated initially from in vitro assays. The IC 50 Doses can be formulated in animal models to achieve a circulating plasma concentration range that includes the therapeutically effective amount (i.e., the concentration of the test conjugate that inhibits half of the maximum number of symptoms). Levels in plasma can be measured, for example, by high performance liquid chromatography or a suitable enzyme activity assay. The efficacy of any particular dose can be measured by bioassay of the appropriate endpoint.

[0140] Unless otherwise indicated, the conjugates may be administered at a dose of approximately 1 μg / kg to 500 mg / kg, depending on the severity of symptoms and progression of the disease. For example, the conjugates may be administered in an outpatient setting, for example, every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more days, or by slow intravenous injection, for example, once a week, twice a week, once a month, or twice a month. The appropriate therapeutically effective dose of the compound is selected by the treating clinician and is in the range of approximately 1 μg / kg to 500 mg / kg, 1 μg / kg to 10 mg / kg, 1 μg / kg to 1 mg / kg, 10 μg / kg to 100 μg / kg, 100 μg / kg to 1 mg / kg, and 500 μg / kg to 5 mg / kg. In some embodiments, a suitable therapeutic dose is selected from, for example, 0.1, 0.25, 0.5, 0.75, 1, 5, 10, 15, 20, 30, 40, 50, 60, 70, and 100 mg / kg.

[0141] The α-galactosidase A-containing complex can be administered intravenously, for example, once every two or four weeks, at a dose of 1.0 mg / kg body weight, with an infusion rate of less than or equal to 10, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, or 33 mg / hour. In another example, the α-glucosidase-containing complex can be administered intravenously, for example, once every two or four weeks, at a dose of 20 mg / kg or 40 mg / kg, for approximately, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours. In some embodiments, the administration rate of α-glucosidase can begin at, for example, 1 mg / kg / hour, then increase to, for example, 2 mg / kg / hour every 30 minutes, and increase to a maximum of, for example, 7 mg / kg / hour after establishing the subject's tolerance to the infusion rate. The complex containing N-acetylgalactosamine-4-sulfatase can be administered by intravenous infusion, for example, at a dose of 1.0 mg / kg body weight every week, for approximately, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours. Further specific dosage examples are described in the Physicians' Desk Reference®.

[0142] III. Methods for Treating Lysosomal Storage Diseases In some embodiments, the present invention provides methods for treating a lysosomal storage disease, e.g., those disclosed in Table 1. In some embodiments, the present invention further provides methods for targeting proteins to lysosomes by conjugation with oligosaccharides comprising mannose-6-phosphate.

[0143] In certain embodiments, the method comprises administering a therapeutically effective amount of an oligosaccharide-protein conjugate of the invention to a subject (including, for example, a mammal, such as a human, cat, dog, mouse, or rat, or an avian, such as a quail) suffering from a lysosomal storage disease. The oligosaccharide-protein conjugate can be a conjugate of an oligosaccharide comprising mannose-6-phosphate, such as an oligosaccharide of any of Formulae I-VI, and a glycoprotein, such as a lysosomal enzyme (e.g., a lysosomal enzyme listed in Table 1). In one embodiment, the method comprises administering to a subject in need thereof a pharmaceutical composition comprising at least one of the conjugates of the invention.

[0144] In certain embodiments, the method comprises administering (1) a conjugate comprising a protein and (2) an oligosaccharide comprising mannose-6-phosphate, such as an oligosaccharide of any of Formulas I-VI, together with one or more other therapies, which may be administered simultaneously (including simultaneously as a mixed formulation), before, or after administration of the conjugate.

[0145] In some embodiments, the method includes treating the subject (before, after, or during treatment with the conjugates described herein) with an antipyretic, antihistamine, and / or immunosuppressant. In some embodiments, the subject may be treated with an antipyretic, antihistamine, and / or immunosuppressant before being treated with the oligosaccharide-glycoprotein conjugate to reduce or prevent infusion-associated reactions. For example, the subject may be pretreated with one or more of acetaminophen, azathioprine, cyclophosphamide, cyclosporine A, diphenhydramine, methotrexate, mycophenolate mofetil, oral steroids, or rapamycin.

[0146] In some embodiments, the method includes treating the subject with one or more of acetaminophen, azathioprine, cyclophosphamide, cyclosporine A, diphenhydramine, methotrexate, mycophenolate mofetil, oral steroids, or rapamycin, e.g., at or about t=0 (the time the conjugate is administered) and / or t=12, 24, 36, 48, 60, 72, 96, 120, and 144 hours, e.g., for the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more conjugate treatments. For example, in some examples, a subject with Fabry disease or Pompe disease may be treated with methotrexate (e.g., 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 25, 30, 35, 40, 50, 60, 70, 80 mg or more of methotrexate per kg), e.g., at or about t=0, 24, and 48 hours, e.g., for the first 1, 2, 3, 4, 5, 6, 7, 8 weeks of treatment with the conjugate. In some embodiments, immune tolerance to the conjugate may be induced in a subject with a lysosomal storage disease, e.g., mucopolysaccharidosis type I, by treatment with cyclosporine A and azathioprine. For example, a subject may be treated with cyclosporine A and azathioprine as described in Kakkis et al., Proc. Natl. Acad. Sci. USA 101:829-834 (2004).

[0147] In some embodiments, the method includes treating the subject (before, after, or during treatment with the conjugate) with small molecule therapy and / or gene therapy, including small molecule therapy and gene therapy performed for the treatment of lysosomal storage disease. Small molecule therapy may include administration of miglustat and / or one or more compounds described, for example, in U.S. Patent Application Publication Nos. 2003 / 0050299, 2003 / 0153768, 2005 / 0222244, and 2005 / 0267094. Gene therapy can be performed, for example, as described in U.S. Patent Application Publication Nos. 5,952,516, 6,066,626, 6,071,890, 6,287,857, and U.S. Patent Application Publication No. 2003 / 0087868.

[0148] The terms "treatment," "method of treatment," and cognates thereof refer to both therapeutic treatment and prophylactic / preventative measures. Thus, those in need of treatment may include individuals already having a particular lysosomal storage disease, as well as those at risk for the disease (i.e., those likely to eventually contract the disease or to develop certain symptoms of the disease).

[0149] A treatment method may result in the prevention or alleviation of symptoms, or other desired biological outcome, and may be assessed by amelioration or delayed onset of clinical signs, increased activity of the metabolic deficiency enzyme, and / or reduced levels of accumulation of the metabolic deficiency enzyme's substrate.

[0150] In some embodiments, the method includes administering to a subject a complex comprising (1) a lysosomal enzyme and (2) an oligosaccharide of any of Formulas I-VI, thereby increasing the activity of a deficient lysosomal enzyme in the subject, e.g., at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, as compared to endogenous activity. In some embodiments, the method includes administering to a subject a complex comprising (1) a lysosomal enzyme and (2) an oligosaccharide of any of Formulas I-VI, thereby increasing the activity of a deficient enzyme in the subject, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, or 1000-fold as compared to endogenous activity. Increased enzyme activity can be measured, e.g., by a reduction in clinical symptoms or by a suitable clinical or biological assay.

[0151] In some embodiments, the method comprises administering to a subject a conjugate of the invention comprising GAA, thereby treating Pompe disease (also known as acid alpha-glucosidase deficiency, acid maltase deficiency, glycogen storage disease type II, glycogen storage disease type II, and lysosomal alpha-glucosidase deficiency). In certain embodiments, recombinant human GAA (rhGAA) is produced using Chinese Hamster Ovary (CHO) cells. In additional embodiments, rhGAA may be conjugated to an oligosaccharide selected from oligosaccharide 103; a mixture of 103 and formula A; oligosaccharide 128, 129, 130, 131, 132, 133, or 136; and any combination thereof. In one embodiment, the oligosaccharide is selected from oligosaccharides 128 and 136. In additional embodiments, at least 5 moles of a conjugate comprising formula A are administered to the patient per mole of GAA.

[0152] In certain embodiments, the patient is an adult who has been diagnosed with Pompe disease, hi other embodiments, the patient is an infant or child.

[0153] Increased GAA activity can be measured, for example, by observing a decrease in lysosomal glycogen accumulation in cardiac myocytes, skeletal muscle cells, or skin fibroblasts, either biochemically (see, for example, Zhu et al., J. Biol. Chem. 279:50336-50341 (2004)) or histologically. GAA activity can also be measured, for example, in muscle biopsy samples, cultured skin fibroblasts, lymphocytes, and dried blood spots. Dried blood spot assays are described, for example, in Umpathysivam et al., Clin. Chem. 47:1378-1383 (2001) and Li et al., Clin. Chem. 50:1785-1796 (2004). Treatment of Pompe disease can also be evaluated, for example, by serum levels of creatine kinase, amplification of motor function (e.g., as assessed by the Alberta Infant Motor Development Test), changes in left ventricular mass index measured by echocardiogram, and cardiac electrical activity measured by electrocardiogram. Administration of GAA complexes can also result in a reduction in one or more symptoms of Pompe disease, such as cardiac hypertrophy, cardiomyopathy, daytime sleepiness, exertional dyspnea, failure to thrive, feeding difficulties, "floppiness," gait disturbance, headache, hypotension, organomegaly (e.g., enlarged heart, tongue, liver), lordosis, balance disorders, lower back pain, morning headache, muscle weakness, respiratory insufficiency, winged scapula, scoliosis, decreased deep tendon reflexes, sleep apnea, susceptibility to respiratory infections, and vomiting.

[0154] In another embodiment, the method comprises treating Fabry disease by administering to the subject a conjugate comprising α-galactosidase A. Fabry disease, or Anderson-Fabry disease, is a rare, X-linked lysosomal storage disease characterized by deficiency of α-galactosidase A, which leads to the accumulation of globotriaosylceramide (GL3) and other neutral glycosphingolipids in visceral tissues and in the lysosomes of endothelial, epithelial and muscle cells. The accumulation of neutral glycosphingolipids in the vasculature leads to vascular narrowing and dilation, ultimately resulting in ischemia and infarction.

[0155] Administration of the complex of the present invention containing α-galactosidase A may result in, for example, acroparesthesia, angina, angiokeratoma, arrhythmia, gait ataxia, burning and / or tingling pain in the extremities, cataracts, cold intolerance, conduction abnormalities, corneal opacities, and the like. whorling, coronary artery disease, dementia, depression, diarrhea, ventricular dilation, dizziness, cardiomegaly, cardiomyopathy, diplopia, dysarthria, fatigue, fever with elevated erythrocyte sedimentation rate, hearing problems, heart disease, heart valve disease, heat intolerance, hemiataxia, hemiparesis, hypohidrosis, hypohidrosis, infarction, ischemia, joint pain, kidney disease, left ventricular hypertrophy, lens abnormalities, lens opacities, lipuria, muscle weakness, myocardial infarction, nausea, nystagmus, pain (e.g., severe pain spreading over the whole body), polydipsia, proteinuria, postprandial pain, renal failure, retinal abnormalities, tinnitus, stomach pain, ST-T changes, stroke, uremia, valvular disease, dizziness, vomiting, and weakness. Administration of α-galactosidase A complex may also result in an increase in α-galactosidase A activity, for example, in plasma, tears, leukocytes, biopsy tissue, or cultured skin fibroblasts. Administration of α-galactosidase A complex may also result in a histological finding of a reduction (e.g., at least a 10% reduction) or disappearance of the increase in birefringent fat globules. It may also result in a reduction in fat globules in the urine sediment, improved renal function measured by serum creatinine level or creatinine clearance, and a reduction in proteinuria. Administration of α-galactosidase A complex may also result in a reduction in GL3 content in the capillary endothelium of the kidney, heart, and skin. Additional assays for measuring the effect of Fabry disease treatment are described, for example, in MacDermott et al., J.Med.Genet.38:750-760 (2001).

[0156] In other embodiments, the method includes administering to a subject a complex of the invention comprising acid sphingomyelinase, thereby treating Niemann-Pick A disease or Niemann-Pick B disease, or acid sphingomyelinase deficiency. Administration of the acid sphingomyelinase complex may result in a reduction in one or more clinical symptoms associated with Niemann-Pick A disease or Niemann-Pick B disease, including, for example, abnormal cholesterol levels, abnormal lipid levels, ataxia, blood abnormalities, cherry red spots in the eyes, frequent lung infections, growth retardation, hepatosplenomegaly, low platelet counts, lymphadenopathy, peripheral neuropathy, lung function problems, shortness of breath, skin pigmentation changes, or xanthomatosis. In some embodiments, the complex may be administered intracranially.

[0157] In another embodiment, the method comprises administering to a subject a conjugate of the invention comprising α-L-iduronidase, thereby treating mucopolysaccharidosis type I (including, for example, Hurler and Hurler-Scheie types of MPS I). Administration of an α-L-iduronidase conjugate may result in a reduction in one or more clinical symptoms of MPSI, such as, for example, aortic regurgitation, aortic stenosis, cartilage tunnel syndrome, chronic rhinitis, conductive hearing loss, constipation, corneal opacity, growth retardation, diarrhea, abdominal distension, lumbar kyphosis, kyphosis, hepatosplenomegaly, hydrocephalus, inguinal hernia, kyphosis, mental retardation, mitral regurgitation, mitral stenosis, night blindness, open angle fibromyalgia, decreased hand function, progressive arthropathy, recurrent respiratory infections, respiratory failure, retinal degeneration, scoliosis, sensorineural hearing loss, severe back pain, rhinorrhea, sleep apnea, spinal cord compression, thenar atrophy, umbilical hernia, and upper respiratory tract complications.

[0158] In yet another embodiment, the method comprises administering to a subject a conjugate of the invention comprising iduronate-2-sulfatase, thereby treating mucopolysaccharidosis type II (Hunter's disease). Administration of the iduronate-2-sulfatase conjugate may result in a reduction in one or more clinical symptoms of MPS type II, including, for example, valvular renal disease, cardiopulmonary insufficiency, cartilaginous tunnel syndrome, chronic diarrhea, chronic papilledema, characteristic facial features, corneal opacity, coronary artery stenosis, hearing loss, dysmorphism, dysostosis, ear infections, hearing impairment, hepatosplenomegaly, hydrocephalus, inguinal hernia, joint stiffness, kyphoscoliosis, mental retardation, cardiomyopathy, myocardial hypertrophy, pulmonary hypertension, retinal dysfunction, skeletal abnormalities, umbilical hernia, upper respiratory tract infections, and valvular dysfunction.

[0159] In yet another embodiment, the method comprises administering to a subject a conjugate of the invention comprising N-acetylgalactosamine-4-sulfatase (arylsulfatase B), thereby treating mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome). Administration of the N-acetylgalactosamine-4-sulfatase conjugate may result in a reduction in one or more clinical symptoms of MPS VI, including, for example, blindness, cardiac abnormalities, cardiopulmonary disease, characteristic facial features, corneal opacity, ear infections, growth retardation, hepatomegaly, hepatosplenomegaly, joint deformities, nerve entrapment syndrome, respiratory distress, skeletal deformities, spinal cord compression, splenomegaly, joint stiffness, and upper airway obstruction.

[0160] The foregoing and following descriptions are exemplary and explanatory only and are not restrictive of the invention, as claimed. EXAMPLES

[0161] Example 1. General procedure for oligosaccharide synthesis A. Glycosylation Glycosylation reactions were carried out using standard methods by coupling donor and acceptor sugars. Briefly, donor and acceptor compounds were dissolved in anhydrous DCM in the presence of heat-activated molecular sieves 4A under dry nitrogen unless otherwise indicated. The solution was cooled and stored at 0°C for ∼30 min, followed by slow addition of TMSOTf (1 eq). Reactions were monitored by TLC (silica gel) with hexane / EtOAc and quenched with TEA or Hunig's base (1.05 eq). The mixtures were filtered, concentrated to a syrup, and purified by flash column chromatography using a hexane / EtOAc gradient unless otherwise indicated.

[0162] B. Acid-Catalyzed Deacetylation In certain embodiments, acetylated compounds are deacetylated prior to glycosylation or other modifications, such as phosphorylation. In the following examples, hydrogen chloride was generated by adding acetyl chloride to cold (0° C.) dry methanol. The concentrated solution was added to a 1:3 solution of the acetylated compound in DCM / methanol. The final concentration was 3% w / v with respect to the methanol content of the solution. The deacetylation reaction was carried out for a) about 18 hours for primary acetates and b) about 48 to 64 hours for secondary acetates. The reaction was quenched with TEA or Hunig's base followed by extraction of DCM or EtOAc with water unless indicated.

[0163] C. Phosphorylation In some instances, sugars undergo site-specific phosphorylation. To a solution of the sugar in dry acetonitrile at room temperature, 5-methyltetrazole (3.4 eq) was added and the mixture was stirred for 30 min under dry nitrogen. Dibenzyldiisopropylphosphoramidite (1.7 eq per OH group) was added and the reaction was stirred until completion (approximately 60 min). The reaction was checked by TLC (silica gel) using hexane / EtOAc. The solution was cooled in ice / water for 15 min and 30% w / v hydrogen peroxide (2 eq) was added. After approximately 60 min, the reaction was complete and excess saturated sodium thiosulfate was added. The mixture was concentrated to a gum, dissolved in EtOAc, washed with half-saturated brine and dried over sodium sulfate. Unless otherwise indicated, the residue was purified by flash chromatography using a hexane / EtOAc gradient.

[0164] Example 2. Synthesis of the disaccharide aminooxyacetamidopropyl 2-O-[6-O-phosphoryl-α-D-mannosyl]-α-D-mannoside (17)

[0165] [ka]

[0166] Allyl α-D-mannoside was prepared according to the method described by Pekari et al., J. Org. Chem. 66:7432 (2001). To allyl-α-D-mannoside (8.68 g, 39.4 mmol) in anhydrous methanol (100 mL) was added 2,3-butanedione (3.63 mL, 86.1 mmol), trimethyl orthoformate (16 mL, 146 mmol), and 10-(+)-camphorsulfonic acid (1.37 g, 5.9 mmol). The mixture was heated under reflux for 9 hours under dry nitrogen. The reaction mixture was quenched with TEA (1 mL), concentrated to a red syrup, and purified by silica gel flash column chromatography using 40–80% EtOAc / hexane to give allyl 3-O,4-O-[dimethoxybutane-2',3'-diyl]-α-D-mannoside 1 as a white solid (3.89 g, 29.4%).

[0167] Compound 1 (2.65 g, 8 mmol) was dissolved in dry pyridine (20 mL), the solution was cooled in an ice / water bath, and t-butyldiphenylsilyl chloride (2.28 mL, 8.7 mmol) was added. After 18 h, pyridine (20 mL) and acetic anhydride (1.6 mL, 16 mmol) were added, and the solution was heated to 50° C. for 16 h, then concentrated to a syrup and coevaporated with toluene. The residue was dissolved in EtOAc (60 mL), washed with 1 M HCl (2×50 mL), saturated sodium bicarbonate (50 mL), and dried over sodium sulfate. The mixture was filtered and concentrated under vacuum, and the solution was concentrated to give allyl 2-O-acetyl-6-Ot-butyldiphenylsilyl-3-O,4-O[dimethoxybutane-2′,3′-diyl]-α-D-mannoside 2 as a syrup (5.0 g).

[0168] Palladium(II) chloride (0.425 g, 2.4 mmol) was added to a stirred solution of 2 (5.0 g, 8 mmol) in anhydrous methanol (25 mL). After about 3 h, the reaction was quenched with TEA (0.75 mL, 4.8 mmol). Methanol was removed under reduced pressure, and the residue was purified by silica gel flash column chromatography using 10-50% EtOAc / hexane to give 2-O-acetyl-6-Ot-butyldiphenylsilyl-3-O,4-O[dimethoxybutane-2',3'-diyl]-α-D-mannoside 3 as a white foam (2.72 g, 59.2%).

[0169] Trichloroacetonitrile (1.75 mL, 17.4 mmol) and DBU (0.05 mL, 0.35 mmol) were added to a solution of 3 (1.0 g, 1.74 mmol) in dry DCM (1 mL). After about 75 min, the solution was directly purified by flash column chromatography on a silica gel column using EtOAc / hexanes (0-30%) to give 2-O-acetyl-6-Ot-butyldiphenylsilyl-3-O,4-O[dimethoxybutane-2',3'-diyl]-α-D-mannose trichloroacetimidate 4 as a white foam (0.98 g, 78.2%). The donor 4 (0.98 g, 1.36 mmol) and acceptor 3-N-benzyloxycarbonylaminopropanol (0.284 g, 1.36 mmol) were converted according to the general glycosylation procedure in Example 1 to give N-benzyloxycarbonylaminopropyl 2-O-acetyl-6-Ot-butyldiphenylsilyl-3-O,4-O[dimethoxybutane-2',3'-diyl]-α-D-mannoside 5 as a white foam (0.66 g, 64%).

[0170] To a solution of 5 (0.66 g, 0.87 mmol) in anhydrous methanol (5 mL) was added a solution of 25% w / v sodium methoxide in methanol (0.05 mL, 0.22 mmol). After approximately 1 h, the reaction was quenched with glacial acetic acid (0.025 mL) and concentrated to a syrup. The product was dissolved in DCM (10 mL), washed with half-saturated brine (5 mL), and dried over sodium sulfate to give N-benzyloxycarbonylaminopropyl 6-Ot-butyldiphenylsilyl-3-O,4-O[dimethoxybutane-2',3'-diyl]-α-D-mannoside 6 (0.58 g, 92%) as a white foam.

[0171] [ka]

[0172] Allyl α-D-mannoside (3.15 g, 14.3 mmol) was dissolved in dry pyridine (20 mL) and cooled in an ice / water bath. t-Butyldiphenylsilyl chloride (4.03 mL, 15.7 mmol) was added and the solution was allowed to warm to room temperature. Stirred for 18 h, benzoyl chloride (5.93 mL, 51.5 mmol) was added and after 24 h the reaction was quenched with water (3 mL) and stirred for 30 min. The solution was concentrated in vacuo and stripped with toluene (3x50 mL). The residue was dissolved in EtOAc (100 mL) and washed with chilled 1M HCl (50 mL), half-saturated brine (50 mL), half-saturated sodium bicarbonate (50 mL), half-saturated brine (50 mL), dried over sodium sulfate, filtered and concentrated to a syrup. Purification by silica gel flash column chromatography using 0-50% EtOAc / hexanes afforded allyl 2,3,4-tri-O-benzoyl-6-Ot-butyldiphenylsilyl-α-D-mannoside 7 as a white foam (8.62 g, 78.2%).

[0173] Glacial acetic acid (11.1 mL, 18.26 mmol) and 1 M tetrabutylammonium fluoride (18.26 mL, 18.26 mmol) were added to a solution of 7 (12.77 g, 16.6 mmol) in dry THF (50 mL). At 80 min, glacial acetic acid (0.15 mL, 25 mmol) and 1 M tetrabutylammonium fluoride (2.5 mL, 25 mmol) were added, and at 90 min, additional glacial acetic acid (0.25 mL, 4.15 mmol) and 1 M tetrabutylammonium fluoride (4.15 mL, 4.15 mmol) were added. After 2 h, the solution was concentrated to half volume and diluted with EtOAc (150 mL). The solution was washed with half-saturated brine (2x150 mL) and half-saturated sodium bicarbonate (200 mL), concentrated, and the residue was purified by silica gel flash column chromatography using 10-50% EtOAc / hexanes to give allyl 2,3,4-tri-O-benzoyl-α-D-mannoside 8 as a white foam (6.75 g, 76.4%). Compound 8 (6.75 g, ymmol) was converted following the general phosphorylation procedure to give allyl 2,3,4-tri-O-benzoyl-6-O-dibenzylphosphoryl-α-D-mannoside 9 as a white foam (9.52 g, 95%).

[0174] Palladium(II) chloride (0.638 g, 3.6 mmol) was added to a solution of 9 (9.52 g, 12.1 mmol) in dry methanol (50 mL). After about 5 h, more palladium(II) (0.145 g) was added and the mixture was stored for 18 h. The solution was filtered, concentrated, and the residue was purified by silica gel flash column chromatography with 20-70% EtOAc / Hexane to give 2,3,4-tri-O-benzoyl-6-O-dibenzylphosphoryl-α-D-mannose 10 as a white foam (3.8 g, 42.5%).

[0175] Trichloroacetonitrile (5.06 mL, 5.1 mmol) and DBU (0.15 mL, 1 mmol) were added to a solution of 10 (3.8 g) in dry DCM under dry nitrogen at 0° C. After approximately 90 min, the solution was directly purified by silica gel flash column chromatography with 10-60% EtOAc / hexanes to give 2,3,4-tri-O-benzoyl-6-O-dibenzylphosphoryl-α-D-mannoside trichloroacetimidate 11 as a white foam (3.3 g, 72.1%).

[0176] [ka]

[0177] Donor 6 (2.62 g, 2.97 mmol) and acceptor 11 (1.92 g, 2.7 mmol) were converted according to the general glycosylation procedure of Example 1 to give N-benzyloxycarbonylaminopropyl 2-O-[2,3,4-tri-O-benzoyl-6-O-dibenzylphosphoryl-α-D-mannosyl]-6-Ot-butyldiphenylsilyl-3-O,4-O[dimethoxybutane-2',3'-diyl]-α-D-mannoside 12 as a white foam (1.27 g, 32.2%).

[0178] [ka]

[0179] TFA / water 19:1 v / v (8.4 mL) was added to an ice / water bath cooled solution of 12 (2.1 g, 1.44 mmol) in DCM (8 mL). After approximately 2 h the starting material was consumed as indicated by TLC. Ethanol (25 mL) was added to this solution which was then concentrated and coevaporated with ethanol (3x25 mL). The residue was dissolved in dry methanol (10 mL) and cooled in an ice / water bath. Acetyl chloride (0.4 mL) was added to give a 3% w / v HCl solution. The solution was allowed to warm to room temperature. After approximately 2 h the starting material was consumed as indicated by TLC. The reaction was quenched with triethylamine (1 mL), concentrated and the residue was purified by silica gel flash column chromatography using 30-100% EtOAc / hexanes to give 13 (0.758 g, 47.9%) as a white foam. To a solution of 13 (0.758 g, 0.69 mmol) in anhydrous methanol (10 mL) was added a solution of 25% w / v sodium methoxide in methanol (0.15 mL). After approximately 1 h the starting material was consumed as shown by tlc. The reaction was quenched with 1M HCl to give 14. To this solution was added glacial acetic acid (25 μL), wet 10% Pd / C (0.1 g) and a hydrogen balloon was attached. After 6 h reaction the product was charred with 5% sulfuric acid / EtOH but was not UV active. The mixture was filtered and concentrated to an oil which was then dissolved in water (10 mL) and lyophilized to give 3-aminopropyl 2-O-[6-O-phosphoryl-α-D-mannosyl]-α-D-mannoside 15 (0.300 g, 91.3% from 13).

[0180] A 0.1M NaOH solution (2 mL) was added to a solution of 15 (0.1 g, 0.21 mmol) in water (8.5 mL), followed by Nt-butoxycarbonyl-aminooxyacetyl 2,3,5,6-tetrafluorophenylate (0.14 g, 0.42 mmol) in THF (8.5 mL). After 18 h, the solution was adjusted to pH 4 with 2M HCl and the solution was extracted with DCM (3x10 mL). The aqueous layer was lyophilized to give Nt-butoxycarbonyl-aminooxyacetamidopropyl 2-O-[6-O-phosphoryl-α-D-mannosyl]-α-D-mannoside 16 (0.12 g). Compound 16 (0.12 g) was dissolved in TFA / DCM 1:1 (10 mL) and the solution was stirred for about 30 min and then concentrated to an oil. This was dissolved in water (5 mL) and the product was lyophilized to give a solid (0.45 g), which was purified using Biogel® P2 and eluted with water to give 17 (0.063 g).

[0181] Example 3. Synthesis of trisaccharide (35)

[0182] [ka]

[0183] 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannose trichloroacetamidate 18 was prepared as described by Yamazaki et al., Carb. Res. 201:31 (1990).

[0184] [ka]

[0185] 6-O-acetyl-3,4,6-tri-O-benzoyl-α-D-mannose trichloroacetimidate 19 was prepared as described in Heng et al., J. Carb. Chem. 20:285 (2001).

[0186] [ka]

[0187] Donor 19 (5.0 g, 7.4 mmol) and acceptor N-9-fluorenylmethylcarbonylaminopropanol (2.41 g, 8.1 mmol) were converted according to the general glycosylation procedure to give a white foam, N-9-fluorenylmethylcarbonylaminopropyl 6-O-acetyl-2,3,4-tri-O-benzoyl-α-D-mannoside 29 (4.0 g, 66.4%).

[0188] [ka]

[0189] Compound 29 (4.0 g, 4.9 mmol) was converted according to the general procedure (b) for acid-catalyzed deacetylation of secondary acetates to give N-9-fluorenylmethylcarbonylaminopropyl 2,3,4-tri-O-benzoyl-α-D-mannoside 30 as a white foam (3.3 g, 87.3%). Donor 18 (3.27 g, 5.16 mmol) and acceptor 30 (3.3 g, 4.3 mmol) were converted according to the general glycosylation procedure to give N-9-fluorenylmethylcarbonylaminopropyl 6-O-[2-O-acetyl-3,4,6-tri-O-benzylmannosyl]-2,3,4-tri-O-benzoyl-α-D-mannoside 31 as a white foam (4.94 g, 92.7%).

[0190] [ka]

[0191] Compound 31 (4.94 g, 3.96 mmol) was converted according to the general procedure (b) for acid-catalyzed deacetylation of secondary acetate to give N-9-fluorenylmethylcarbonylaminopropyl 6-O-[3,4,6-tri-O-benzylmannosyl]-2,3,4-tri-O-benzoyl-α-D-mannoside 32 as a white foam (1.73 g, 36%). Compound 11 was prepared according to the method of Example 2. Donor 11 (3.37 g, 3.74 mmol) and acceptor 32 (1.73 g, 1.44 mmol) were converted according to the general glycosylation procedure to give 33 as a white foam (1.2 g, 43.1%).

[0192] [ka]

[0193] To a solution of 33 (1.2 g, 0.62 mmol) in anhydrous THF (10 mL) was added dodecylthiol (1.48 mL, 6.2 mmol) and diazabicycloundec-7-ene (DBU) (0.093 mL, 0.62 mmol). After approximately 18 h, the starting material was consumed as indicated by tlc. The solution was concentrated to a syrup and purified by silica gel column chromatography using 0-20% methanol / DCM. The product was added to methanol / water 1:1 (20 mL) and acetic acid (25 μL) and fitted with Pd / C (0.1 g) and a balloon of hydrogen. After 18 h, the solution was filtered through Celite and concentrated to a white foam. The foam was dissolved in dry methanol (10 mL) and a solution of 25% w / v sodium methoxide in methanol (0.15 mL), after 6 h the solution was concentrated, taken up in water (10 mL) and washed with DCM (10 mL). The aqueous layer was lyophilized to give aminopropyl 6-O-([α-D-mannosyl]-2-O-[6-O-phosphoryl-α-D-mannosyl])-α-D-mannoside 34 as the disodium salt (0.27 g, 63.5% from 33).

[0194] To 34 (0.17 g, 0.3 mmol) in 1:1 water / DMSO solution (10 mL) was added a solution of Nt-butoxycarbonylamino-oxyacetyl 2,3,5,6-tetrafluorophenylate (0.34 g, 1.14 mmol) in DMSO (2 mL) and a solution of 3-hydroxy-1,2,3-benzotriazin-4(3H)-one (DHBT) (0.09 g, 0.6 mmol) in DMSO (1 mL). After 24 h, the solution was purified using sephadex size exclusion resin. Fractions were confirmed by charring on silica gel plates, and selected fractions were combined and lyophilized to give a solid. Dissolved in TFA / DCM (8 mL), stirred for 60 min, then concentrated to an oil. Water (5 mL) was added and the product was purified using sephadex size exclusion resin. Fractions were confirmed by charring on silica gel plates, and selected fractions were combined and lyophilized to give 35 (0.033 g, 16.4% from 34).

[0195] Example 4: Synthesis of tetrasaccharide A. Aminooxyacetamido 1,5-di-3-amidopropyl[2-O-[6-O-phosphoryl-α-D-mannosyl]-α-D-mannosyl]glutamic acid (28)

[0196] [ka]

[0197] Compound 19 was prepared according to the method described in Example 3. Donor 19 (15.49 g, 24.3 mmol) and acceptor 3-N-9-fluorenylmethoxycarbonylaminopropanol (8.7 g, 29.19 mmol) were converted according to the general glycosylation procedure to give N-9-fluorenylmethoxycarbonylaminopropyl 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannoside 20 as a white foam (10.55 g, 55%).

[0198] [ka]

[0199] To a solution of 20 (10.5 g, ymmol) in dry DCM (50 mL) and anhydrous methanol (100 mL) was added acetyl chloride (4.8 mL, 63 mmol) dropwise over approximately 30 min to give a 2.3% w / v HCl in methanol solution. After approximately 18 h, the reaction was quenched with Hunig's base (9.81 mL, 63 mmol) and an additional 1.5 mL was added. The solution was concentrated to a syrup, coevaporated with chloroform (2x50 mL), dissolved in DCM (100 mL), washed with half-saturated brine (100 mL), and dried over sodium sulfate. The solution was concentrated and purified by silica gel flash column chromatography with 0-100% EtOAc / hexane to give N-9-fluorenylmethoxycarbonylaminopropyl 3,4,6-tri-O-benzyl-α-D-mannoside 21 (6.11 g, 61.2%) as a white foam. Donor 21 (6.11 g, 13.4 mmol) and acceptor 11 (7.1 g, 7.9 mmol) were converted according to the general glycosylation procedure to give N-9-fluorenylmethoxycarbonylaminopropyl 2-O-[6-O-dibenzylphosphoryl-2,3,4-tri-O-benzoyl-α-D-mannosyl]-3,4,6-tri-O-benzyl-α-D-mannoside 22 as a white foam (5.8 g, 50.1%).

[0200] To a solution of 22 (5.8 g, 3.96 mmol) in anhydrous THF (75 mL) was added dodecylthiol (9.53 mL, 40 mmol) and DBU (0.6 mL, 4 mmol). After approximately 4 h, the reaction was quenched with methanolic HCl (5.6 mL, 8 mmol) and concentrated to a syrup. The product was triturated with diethyl ether to give 3-aminopropyl 2-O-[2,3,4-tri-O-benzoyl-α-D-mannosyl]-3,4,6-tri-O-benzyl-α-D-mannoside hydrochloride 23 as a gum (3.77 g, 74.5%).

[0201] [ka]

[0202] To a solution of 23 (3.77 g, 2.95 mmol) in dry acetonitrile (50 mL) was added N-benzyloxycarbonylglutamic acid (0.3661 g, 1.3 mmol), N-hydroxybenzotriazole (HOBt) (0.4 g, 2.95 mmol), DBU (4.6 mL, 4 mmol), and 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC) (0.75 g, 8.85 mmol). After 16 h, Hunig's base (0.25 mL) was added, followed by more EDC (0.75 g, 8.85 mmol). After 21 h, the solution was concentrated to a syrup and purified by silica gel flash column chromatography using 10% 2-propanol / DCM in 0-50% DCM to give N-benzyloxycarbonylamino 1,5-di-[3-amidopropyl 2-O-[2,3,4-tri-O-benzoyl-6-O-dibenzylphosphoryl-α-D-mannosyl]-3,4,6-tri-O-benzyl-α-D-mannosyl]glutamic acid 24 as a white foam (0.97 g, 11.2%).

[0203] To a solution of 24 (0.912 g, 0.33 mmol) in anhydrous DCM (20 mL) and methanol (25 mL) was added a solution of 25% w / v sodium methoxide in methanol (0.09 mL, 0.41 mmol). After approximately 6.5 h, the reaction was quenched with 1 M HCl (0.41 mL, 0.41 mmol), concentrated to a syrup, and purified by silica gel flash column chromatography using 0-100% DCM to 10% 2-propanol / DCM to give N-benzyloxycarbonylamino 1,5-di-3-aminopropyl[2-O-[6-O-dibenzylphosphoryl-α-D-mannosyl]-3,4,6-tri-O-benzyl-α-D-mannosyl]glutamic acid 25 (0.306 g, 44.4%).

[0204] A stirred solution of 25 (0.3 g, 0.144 mmol) in THF / water 2:1 v / v (75 mL) was fitted with 10% wet Pd / C (0.052 g) and a hydrogen balloon. After 16 h, glacial acetic acid (25 μL) was added and a fresh hydrogen balloon was fitted. After 6 h, more 10% Pd / C (0.04 g) was added and more hydrogen was added. After 18 h, fresh 5% Pd / C (0.05 g) was added and more hydrogen was added. After 24 h, the product was charred with 5% sulfuric acid / EtOH but was not UV active. The mixture was filtered through Celite, the pad was washed and concentrated to approximately 30% to remove THF. Subsequent lyophilization gave 1,5-di-3-amidopropyl[2-O-[6-O-phosphoryl-α-D-mannosyl]-α-D-mannosyl]glutamic acid 26 (0.121 g, 77.9%).

[0205] A solution of Nt-butoxycarbonylaminooxyacetyl 2,3,5,6-tetrafluorophenylate (0.19 g, 0.57 mmol) in DMSO (1 mL) and a solution of 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (DHBT) (0.052 g, 0.3 mmol) in DMSO (1 mL) were added to a solution of 26 (0.16 g, 0.15 mmol) in water / DMSO 1:1 (7.5 mL). After 18 h, the solution was purified on a sephadex size exclusion resin. Fractions were confirmed by charring on silica gel, selected fractions were combined and lyophilized to give Nt-butoxycarbonylaminooxyacetamido 1,5-di-3-amidopropyl[2-O-[6-O-phosphoryl-α-D-mannosyl]-α-D-mannosyl]glutamic acid 27 (0.095 g, 42.1%). To compound 27 was added TFA / DCM 1:1 (8 mL) and the mixture was stirred until dissolved (approximately 60 min) and then concentrated to an oil. Water (10 mL) was added and the product was purified on sephadex size exclusion resin. Fractions were confirmed by charring on silica gel plates, selected fractions were combined and lyophilized to give 28 (0.048 g, 54.2%).

[0206] B. Aminooxyacetamidopropyl 6-O-([α-D-mannosyl]-6-O-[α-D-mannosyl]-2-O-[6-O-phosphoryl-α-D-mannosyl])-α-D-mannoside (47)

[0207] [ka]

[0208] Compound 11 was prepared as described in Example 2. The donor 11 (5.0 g, 7.4 mmol) and the acceptor 3-N-benzyloxycarbonylaminopropanol (1.93 g, 9.25 mmol) were converted according to the general glycosylation procedure of Example 1 to give a white foam. The product was converted according to the general procedure of acid-catalyzed deacetylation of the primary acetate to give N-benzyloxycarbonylaminopropyl 2,3,4-tri-O-benzoyl-α-D-mannoside 36 as a white foam.

[0209] [ka]

[0210] Donor 19 (4.47 g, 6.6 mmol) and acceptor 36 (3.6 g, 5.3 mmol) were converted according to the general glycosylation procedure of Example 1 to give N-benzyloxycarbonylaminopropyl 6-O-([6-O-acetyl-2,3,4-tri-O-benzoyl-α-D-mannosyl])-2,3,4-tri-O-benzoyl-α-D-mannoside 37 as a white foam (3.8 g, 63.3%). Compound 37 (3.8 g, 3.17 mmol) was converted following the general procedure of acid-catalyzed deacetylation of primary acetate to give N-benzyloxycarbonylaminopropyl 6-O-[2,3,4-tri-O-benzoyl-α-D-mannosyl]-2,3,4-tri-O-benzoyl-α-D-mannoside 38 as a white foam (3.5 g, 95.3%).

[0211] Compound 18 was prepared according to the method described in Yamazaki et al., Carb. Res. 201:31 (1990). Donor 18 (2.41 g, 3.75 mmol) and acceptor 38 (3.5 g, 3 mmol) were converted according to the general glycosylation procedure of Example 1 to give N-benzyloxycarbonylaminopropyl 6-O-([2,3,4-tri-O-benzoyl-α-D-mannosyl]-6-O-[2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannosyl])-2,3,4-tri-O-benzoyl-α-D-mannoside 39 as an oil (5.63 g). Compound 39 (5.83 g) was converted according to the general procedure of acid-catalyzed deacetylation of secondary acetates (see Example 1) to give N-benzyloxycarbonyl-aminopropyl 6-O-([2,3,4-tri-O-benzoyl-α-D-mannosyl]-6-O-[3,4,6-tri-O-benzyl-α-D-mannosyl])-2,3,4-tri-O-benzoyl-α-D-mannoside 40 as a white foam (2.0 g, 41.9% from 38). Donor 19 (1.07 g, 1.63 mmol) and acceptor 41 (2.0 g, 1.3 mmol) were converted according to the general glycosylation procedure to give N-benzyloxycarbonylaminopropyl 6-O-([2,3,4-tri-O-benzoyl-α-D-mannosyl]-6-O-[3,4,6-tri-O-benzyl-α-D-mannosyl]-2-O-[6-O-acetyl-2,3,4-tri-O-benzoyl-α-D-mannosyl])-2,3,4-tri-O-benzoyl-α-D-mannoside 42 as a white foam (1.4 g, 50.8%). Compound 42 (1.4 g, 0.066 mmol) was converted following the general procedure of acid-catalyzed deacetylation of primary acetate to give N-benzyloxycarbonyl-aminopropyl 6-O-([2,3,4-tri-O-benzoyl-α-D-mannosyl])-6-O-[3,4,6-tri-O-benzyl-α-D-mannosyl]-2-O-[2,3,4-tri-O-benzoyl-α-D-mannosyl])-2,3,4-tri-O-benzoyl-α-D-mannoside 43 as a white foam (1.0 g, 80%).Compound 43 (1.0 g, 0.048 mmol) was converted according to the general phosphorylation procedure to give N-benzyloxycarbonylaminopropyl 6-O-([2,3,4-tri-O-benzoyl-α-D-mannosyl]-6-O-[3,4,6-tri-O-benzyl-α-D-mannosyl]-2-O-[6-O-dibenzylphosphoryl-2,3,4-tri-O-benzoyl-α-D-mannosyl])-2,3,4-tri-O-benzoyl-α-D-mannoside 44 as a white foam (0.9 g, 80.7%).

[0212] [ka]

[0213] To a solution of 44 (0.9 g, 0.039 mmol) in anhydrous methanol (20 mL) was added a solution of 25% w / v sodium methoxide in methanol (0.09 mL, 0.4 mmol). After about 7 h, the reaction was quenched with 1 M HCl (0.5 mL), 10% Pd / C (0.2 g), and water (10 mL). The mixture was kept under a hydrogen balloon for 24 h. The mixture was filtered through Celite and washed with EtOAc (20 mL). The solution was lyophilized to give a white solid, N-benzyloxycarbonyl-aminopropyl 6-O-([α-D-mannosyl]-6-O-[3,4,6-tri-O-benzyl-α-D-mannosyl]-2-O-[6-O-dibenzyl-phosphoryl-α-D-mannosyl])-α-D-mannoside 45 (0.23 g, 74.7% from 44).

[0214] A solution of Nt-butoxycarbonylaminooxyacetyl 2,3,5,6-tetrafluorophenylate (0.375 g, 1.14 mmol) in DMSO (2 mL) and a solution of DHBT (0.1 g, 0.6 mmol) in DMSO (1 mL) were added to a solution of 45 (0.23 g, 0.3 mmol) in water / DMSO 1:1 (10 mL). After 24 h, the solution was purified on a sephadex size-exclusion resin. Fractions were confirmed by charring on a silica gel plate, and selected fractions were pooled and lyophilized. The product was reacylated in water / DMSO 1:1 (10 mL) with a solution of Nt-butoxycarbonylaminooxyacetyl 2,3,5,6-tetrafluorophenylate (0.375 g, 1.14 mmol) in DMSO (2 mL) and a solution of DHBT (0.1 g, 0.6 mmol) in DMSO (1 mL). After 24 hours, the solution was purified on sephadex size exclusion resin, fractions were combined and lyophilized to give Nt-butoxycarbonylaminooxyacetamidopropyl 6-O-([α-D-mannosyl]-6-O-[α-D-mannosyl]-2-O-[6-O-phosphoryl-α-D-mannosyl])-α-D-mannoside 46 (0.11 g, 37.5%). Compound 46 was dissolved in TFA / DCM (8 mL) and added. The solution was stirred for 60 minutes and then concentrated to an oil. Water (5 mL) was added and the product was purified on sephadex size exclusion resin. Fractions were confirmed by charring on silica gel plates and selected fractions were combined and lyophilized to give 47 (0.07 g, 70.7%).

[0215] Example 5: Synthesis of β-linked hexasaccharide A. Methylcrotonyl 3,4,6-tri-O-benzyl-β-D-mannoside (51)

[0216] [ka]

[0217] 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannose was prepared as described by Mayer et al., Eur J. Org. Chem. 10:2563 (1999). 25% w / v sodium methoxide in methanol (0.5 mL) was added to a solution of 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannose (8.0 g, 23.3 mmol) in anhydrous methanol (50 mL). After approximately 2 hours, the starting material was consumed as shown by thin layer chromatography (TLC). The reaction was quenched with Amberlite IR120 (H+) resin, filtered, and concentrated to a syrup to give 3,4,6-tri-O-benzyl-α-D-mannose 50 (6.67 g, 99%). Toluene (150 mL) was added to compound 50, followed by dibutyltin oxide (3.88 g, 16.28 mmol) and the mixture was heated under reflux with a Dean-Stark condenser for 3 h. The resulting solution was cooled, concentrated to a syrup, and dissolved in dry DMF (50 mL). Cesium fluoride (2.28 g, 12.1 mmol), tetrabutylammonium iodide (5.47 g, 14.8 mmol), and methyl 4-bromocrotonate (2.46 mL, 22.2 mmol, technical grade) were added to the mixture and heated at about 60° C. for 18 h. The mixture was allowed to cool and filtered to remove solids. It was diluted with isopropyl ether / EtOAc 3.7:1 (380 mL) and washed with half-saturated sodium thiosulfate (240 mL). The aqueous phase was extracted with isopropyl ether / EtOAc 3.7:1 (2×190 mL) and the organic layers were combined and concentrated. The syrup was evaporated with isopropanol (2x25mL) and purified by flash column chromatography using 0-50% EtOAc / hexane to give 51 as a syrup (4.58g, 56.4%). 1 J 1C,1H (100MHz), 157Hz (β<160Hz, α>170Hz)

[0218] B. Methylbutyryl 3,4,6-tri-O-benzyl-β-D-mannoside (52) Compound 50 was prepared as described in Example 2. Toluene (200 mL) was added to compound 50 (9.4 g, 21 mmol), followed by dibutyltin oxide (5.49 g, 22 mmol) and the mixture was heated under reflux with a Dean-Stark condenser for 23 h. The resulting solution was cooled, concentrated to a syrup and dissolved in dry DMF (100 mL). Methyl 4-bromobutyrate (4.23 mL, 32 mmol), tetrabutylammonium iodide (1.94 g, 5.25 mmol), cesium fluoride (3.91 g, 25.5 mmol) were added and the mixture was heated at 60° C. for 2 h and then at ambient temperature for 18 h. The mixture was allowed to cool and filtered through Celite, washing with EtOAc (50 mL). Concentration to a gum, coevaporation with toluene (3x40 mL), adsorption onto silica, and purification by flash chromatography using 0-70% EtOAc / hexanes gave 52 as an oil (9.11 g, 78.6%). 1 J 1C,1H (100 MHz), 157.2 Hz (β<160 Hz, α>170 Hz). No α-linked products were observed.

[0219] [ka]

[0220] C. Methylbutyryl 2-O-[6-O-phosphoryl-α-D-mannosyl]-β-D-mannoside (57) Compound 52 was prepared as described in Example 2, and 6-O-acetyl-3,4,6-tri-O-benzoyl-α-D-mannose trichloroacetimidate 19 was prepared according to the method of Heng et al., J. Carb. Chem. 20:285 (2001). Donor 19 (4.29 g, 6.36 mmol) and acceptor 52 (2.9 g, 5.3 mmol) were converted according to the general glycosylation procedure of Example 1 to give methylbutyryl 2-O-[6-O-acetyl-2,3,4-tri-O-benzoyl-α-D-mannosyl]-3,4,6-tri-O-benzyl-β-D-mannoside 53 as a white foam (4.41 g, 78.5%). Compound 53 (4.41 g, 4.1 mmol) was converted according to the general procedure of acid-catalyzed deacetylation of primary acetates described in Example 1 to give methylbutyryl 2-O-[2,3,4-tri-O-benzoyl-α-D-mannosyl]-3,4,6-tri-O-benzyl-β-D-mannoside 54 as a white foam (2.25 g, 53.7%). Compound 54 (2.25 g, 2.2 mmol) was converted according to the general phosphorylation procedure of Example 1 to give methylbutyryl 2-O-[2,3,4-tri-O-benzoyl-6-dibenzylphosphoryl-α-D-mannosyl]-3,4,6-tri-O-benzyl-β-D-mannoside 55 as a white foam (2.2 g, 77.7%).

[0221] [ka]

[0222] To deprotect 55, a solution of 25% w / v sodium methoxide in methanol (0.2 mL) was added to a solution of 55 (2.2 g, 1.7 mmol) in anhydrous methanol (20 mL). After approximately 24 h, TLC indicated that the starting material had been consumed. The reaction was quenched with Amberlite IR120 (H+) and concentrated to a syrup. The solution was concentrated and purified by silica gel flash column chromatography to give methylbutyryl 2-O-[6-O-dibenzylphosphoryl-α-D-mannosyl]-3,4,6-tri-O-benzyl-β-D-mannoside 56 as a white foam (1.10 g, 67%).

[0223] To a stirred solution of 56 (1.10 g, 1.15 mmol) in THF / water (20 mL) was added glacial acetic acid (25 μL) and fitted with 10% wet Pd / C (0.1 g) and a hydrogen balloon. After reaction for 24 h, the product was charred with 5% sulfuric acid / EtOH but was not visible under UV. The mixture was filtered through Celite and the pad was washed with water (20 mL). The solution was concentrated and dried under vacuum to give methylbutyryl 2-O-[6-O-phosphoryl-α-D-mannosyl]-β-D-mannoside 57 (0.6 g, 98%).

[0224] [ka]

[0225] D. Aminooxyacetamidohydrazide butyl 2-O-[6-O-phosphoryl-α-D-mannosyl]-β-D-mannoside (60) Hydrazine monohydrate (0.44 mL, 5.75 mmol) was added to a stirred solution of 57 (0.6 g, 1.15 mmol) in methanol (20 mL). After 30 min, water (5 mL) was added and the solution was stirred for 18 h. More hydrazine (0.44 mL, 5.75 mmol) was added and the mixture was stirred for 120 h. The solution was concentrated to approximately 25% volume, coevaporated with water (2x10 mL) and the product was lyophilized to give hydrazidobutyl 2-O-[6-O-phosphoryl-α-D-mannosyl]-β-D-mannoside 58 as an off-white solid (0.6 g, 99%).

[0226] To 58 (0.2 g, 0.38 mmol) in DMSO / water 1:1 (10 mL) was added a solution of Nt-butoxycarbonylaminooxyacetyl 2,3,5,6-tetrafluorophenylate (0.49 g, 1.52 mmol) in DMSO (2 mL) and a solution of DHBT (0.125 g, 0.76 mmol) in DMSO (2 mL). After 18 h, the solution was purified on a sephadex size-exclusion resin. Fractions were confirmed by charring on a silica gel plate, and selected fractions were combined and lyophilized to give Nt-butoxycarbonylamino-oxyacetamidohydrazide butyl 2-O-[6-O-phosphoryl-α-D-mannosyl]-β-D-mannoside 59 as an off-white solid (0.1 g, 37.8%). Compound 59 was dissolved in TFA / DCM 1:1 (8 mL). The solution was stirred for about 60 min and then concentrated to an oil. Water (10 mL) was added and the product was purified on sephadex size exclusion resin. Fractions were confirmed by charring on silica gel plates and selected fractions were combined and lyophilized to give 60 as an off-white solid (0.045 g, 52.5%).

[0227] [ka]

[0228] E. Large-Scale Synthesis of Methylbutyryl 3-O-allyl-6-O-trityl-β-D-mannoside (64) A solution of 50.0 kg (128.09 mol) d-mannose pentaacetate in 100 L CHCl was treated with 26.8 kg (243.2 mol, 1.90 eq.) thiophenol and 27.3 kg (192.3 mol, 1.50 eq.) boron trifluoride diethyl etherate, the resulting solution was stirred at 22° C. for 40 hours, and the reaction was judged to be complete by HPLC analysis. 115 L of 5N aqueous NaOH was then carefully charged to the stirred reaction vessel, and the separated layers and the organic layer were washed once more with 46 L of 5N NaOH. The CHCl was removed by distillation under reduced pressure, and the residue was redissolved in 100 kg of isopropanol at 60° C. Upon cooling to 9° C., the product F1 crystallized and was isolated by filtration followed by washing with isopropanol to give 35.8 kg (63%).

[0229] 35.80 kg of F1 (88.28 mol) was suspended in 143 kg of MeOH at 22° C. and treated with 0.73 kg of 30% sodium methoxide in methanol (4.05 mol, 0.046 eq.) to give a clear solution. After the reaction was judged to be complete by TLC analysis, 0.49 kg of acetic acid (8.14 mol, 0.09 eq.) was added and the solvent was removed under reduced pressure. The residue was suspended in toluene, concentrated again under reduced pressure and finally treated with acetone to crystallize the product phenyl-α-D-thiomannoside. After filtration, washing and drying, 19.65 kg yield (89%) was obtained.

[0230] A solution of phenyl-α-D-thiomannoside (19.25 kg, 70.69 mol) in pyridine (43.8 kg) was added to a solution of triphenylmethyl chloride (19.7 kg, 70.66 mol) in toluene (89 kg) at 40° C. and stirred for 22 h. After the reaction was judged complete by HPLC analysis, the solvent was removed under reduced pressure and the residue was dissolved in toluene and reconcentrated. After further dilution with toluene, the solution was washed once with water. The product was precipitated by addition of the toluene solution to a mixture of hexane (840 L) and diisopropyl ether (250 L), filtered and dried to give phenyl 6-O-trityl-1-thio-α-D-mannoside 61 (32.30 kg, 89%).

[0231] [ka]

[0232] A mixture of 61 (30.0 kg, 58.29 mol) and dibutyltin oxide (20.3 kg, 81.5 mol) in toluene (500 kg) was heated under reflux for 2 h until no more water separated from the condensed solvent vapors. The solution was cooled to 40 °C and DMF (34 kg) was added. Approximately half of the total solvent was removed under reduced pressure, DMF (216 kg) was added, and the solution was concentrated again to approximately half the volume. More DMF (250 kg) was added, followed by cesium fluoride (8.9 kg, 58.59 mol), a solution of tetrabutylammonium iodide (23.6 kg, 63.89 mol) in DMF (65 kg), and allyl bromide (21.1 kg, 174.4 mol). The resulting mixture was stirred at 50 °C for 15 h. After the reaction was judged complete by HPLC analysis, the solids were removed from the reaction mixture by filtration and the filtrate was treated with a mixture of diisopropyl ether (136 kg) and ethyl acetate (30 kg), followed by 10% w / w aqueous sodium thiosulfate (300 kg). After phase separation, the lower phase was re-extracted four times with a mixture of diisopropyl ether (136 kg) and ethyl acetate (30 kg) and the combined upper phase was washed three times with water (150 kg). The upper phase was concentrated under reduced pressure and the residue was dissolved in ethanol (160 kg) at 75°C. Upon cooling to 0°C, the product crystallized and could be isolated by filtration. After washing and drying the filter solid, phenyl 3-O-allyl-6-O-trityl-1-thio-α-D-mannoside 62 was obtained (15 kg, 46%).

[0233] [ka]

[0234] A solution of 62 (12.5 kg, 22.53 mol) in a mixture of THF (63 kg) and pyridine (18 kg, 227.5 mol) was treated with toluenesulfonic acid monohydrate (16.7 kg, 87.79 mol) in water (10.7 kg), followed by a solution of N-chlorosuccinimide (9.6 kg, 71.89 mol) in a mixture of water (17 kg) and THF (83 kg) at 15° C. The resulting mixture was warmed to 22° C. and stirred for 3 h. After the reaction was judged complete by HPLC analysis, a solution of sodium thiosulfate (4.6 kg, 29.11 mol) in water (15 kg) was added to the reaction mixture. The phases were separated, the upper phase was concentrated under reduced pressure, and the residue was dissolved in toluene and concentrated again. The residue was redissolved in ethyl acetate and washed with water followed by 16% w / w aqueous sodium chloride solution. After distilling off the ethyl acetate, the crude product was purified by column chromatography on >52 kg of silica gel and eluted with a gradient of 3–10% v / v ethyl acetate / toluene to give 3-O-allyl-6-trityl-α-D-mannose 63 (7.7 kg, 73%).

[0235] [ka]

[0236] A mixture of 63 (7.7 kg, 16.65 mol) and dibutyltin oxide (4.56 kg, 18.32 mol) in methanol (61 kg) was heated under reflux until a cloudy solution was obtained, then heated for an additional hour. The solution was cooled to 25° C., approximately half of the total solvent was removed under reduced pressure, DMF (33 kg) was added, and the solution was concentrated again to approximately half the volume. More DMF (15 kg) was added, followed by cesium fluoride (2.53 kg, 16.65 mol), tetrabutylammonium iodide (6.15 kg, 16.65 mol) in DMF (17 kg), and methyl 4-bromobutyrate (4.52 kg, 24.97 mol). The resulting mixture was stirred at 80° C. for 5 hours. The solids were removed from the reaction mixture by filtration and the filtrate was treated with a mixture of diisopropyl ether (41 kg), ethyl acetate (14 kg) and 10% w / w aqueous sodium thiosulfate (77 kg). After phase separation, the lower phase was re-extracted with a mixture of diisopropyl ether (41 kg) and ethyl acetate (51 kg) and the combined upper phases were washed with water (39 kg). The upper phase was concentrated under reduced pressure and the residue was dissolved in methanol (35 kg).

[0237] To improve the reaction yield, the coupling process was repeated. The dissolved residue was again concentrated under reduced pressure and then diluted with methanol (122 kg). Methanol (60 L) was again distilled off, the resulting solution was treated with dibutyltin oxide (2.28 kg, 9.16 mol), and the mixture was heated under reflux for 2 hours. The solution was cooled to 29°C, approximately half of the total solvent was distilled off under reduced pressure, DMF (37 kg) was added, and the solution was again concentrated to approximately half the volume. More DMF (15 kg) was added, followed by cesium fluoride (1.26 kg, 8.29 mol), a solution of tetrabutylammonium iodide (3.7 kg, 10.02 mol) in DMF (17 kg), and methyl 4-bromobutyrate (3.06 kg, 16.90 mol), and the resulting mixture was stirred at 80°C for 2 hours. After the reaction was judged complete by HPLC analysis, solids were removed from the reaction mixture by filtration and the filtrate was treated with a mixture of diisopropyl ether (25 kg), ethyl acetate (32 kg), and 10% w / w aqueous sodium thiosulfate (77 kg). After separation of the phases, the lower phase was re-extracted with a mixture of diisopropyl ether (25 kg) and ethyl acetate (32 kg) and the combined upper phases were washed with water (39 kg). The solution was concentrated under reduced pressure and the residue was redissolved in toluene (43 kg) and finally concentrated to a volume of approximately 30 L. The crude methyl ester of 64 was then purified by column chromatography on 50 kg of silica gel eluted with a gradient of 5–30% v / v ethyl acetate / toluene.

[0238] A solution of the purified methyl ester in methanol (50 kg) was treated with a mixture of 30% w / w aqueous sodium hydroxide (3.29 kg) and methanol (7.7 kg) and the resulting solution was stirred for 14 hours. The reaction was judged to be complete by HPLC analysis and the reaction mixture was treated with a mixture of diisopropyl ether (41 kg) and ethyl acetate (14 kg) followed by water (77 kg). The biphasic mixture was passed through a 1.2 μm filter cartridge and the phases separated. The lower phase was treated with a mixture of diisopropyl ether (41 kg) and ethyl acetate (14 kg) and the pH of the lower phase was lowered to 4.5-5 by the addition of 5% w / w aqueous citric acid (38 L). The phases were separated and the lower phase was extracted with a mixture of diisopropyl ether (41 kg) and ethyl acetate (14 kg). The combined upper phases were washed with water (39 kg) and then concentrated under reduced pressure. The residue was mixed with diisopropyl ether (39 kg) and the solvent was partially concentrated to give a final volume of about 20 L, allowing the product to crystallize and be isolated by filtration. After washing and drying the filter solid, (3-O-allyl-6-O-trityl-β-D-mannosyl)-4-butanoic acid 64 was obtained (4.7 kg, 51.5%).

[0239] [ka]

[0240] F. Large-Scale Synthesis of Tetrasaccharide Intermediate (69) Compound 64 was prepared according to the method in Part E. The protecting group of 64 was modified before further glycosylation reaction. A solution of 64 (4.25 kg, 7.75 mol) in THF (14 kg) was carefully added to a stirred slurry of 60% sodium hydride dispersion (1.55 kg, 38.75 mol) in THF (45 kg), and the resulting suspension was stirred until hydrogen evolution ceased. A suspension of tetrabutylammonium iodide (0.29 g, 0.78 mol) in THF (2 kg) was charged to the reaction vessel, followed by benzyl bromide (9.2 kg, 53.79 mol). The mixture was stirred at 22° C. for 46 h, then at 30° C. for 12 h, and at 35° C. for 48 h. After HPLC analysis showed the reaction was complete, the mixture was cooled to 0°C and anhydrous methanol (0.7 kg, 21.87 mol) was carefully charged followed by a 30% w / w solution of sodium methoxide (2.1 kg, 11.66 mol) in methanol. Acetic acid (1.4 kg) was then added followed by triethylamine (9.4 kg, 92.89 mol) and the mixture was stirred for 18 h. To the resulting suspension, water (31 kg) was added and the two phases were separated. The upper phase was concentrated under reduced pressure and the residue was dissolved in toluene and concentrated again to a final volume of about 20 L. The crude product was purified by column chromatography on 42 kg of silica gel and eluted with a gradient of 5-15% ethyl acetate / hexane to give methylbutyryl 3-O-allyl-2,4-di-O-benzyl-6-O-trityl-β-D-mannoside 65 as a solution in ethyl acetate (4.4 kg, 77%).

[0241] [ka]

[0242] To a solution of 65 (4.4 kg, 5.92 mol) in methanol (19 kg) at 37° C. was added a solution of toluenesulfonic acid monohydrate (0.9 kg, 4.73 mol) in methanol (6.3 kg) and the resulting mixture was stirred for 1 h. After the reaction was judged to be complete by HPLC analysis, triethylamine (1.5 kg, 14.82 mol) was charged and the solution was concentrated under reduced pressure. Toluene (28 kg) was then added and the solution was washed with water (32 kg). The phases were separated and the upper phase was concentrated under reduced pressure. The crude product was purified by silica gel chromatography on silica gel (32 kg) eluted with a gradient of 9%, then 17%, then 50% v / v ethyl acetate / toluene to give methylbutyryl 3-O-allyl-2,4-di-O-benzyl-β-D-mannoside 66 as a toluene solution (2.67 kg, 90%).

[0243] [ka]

[0244] 3.73 kg (5.49 mol, 1.10 eq.) of 19 and 2.50 kg (4.99 mol) of 66 were dissolved in 34 kg of dry toluene, of which approximately 10 L was distilled off under reduced pressure. The solution was then cooled to 0°C and treated dropwise with 22 g (0.099 mol, 0.02 eq.) of TMSOTf while maintaining the reaction temperature at <5°C. After addition was complete, the mixture was stirred at 0°C for 1 h. After the reaction was judged complete by HPLC analysis, the mixture was neutralized by the addition of 30 g (0.296 mol, 0.06 eq.) of Et3N. Hexane (22 L) was added, the resulting suspension was filtered, and the filtrate was washed with 33 L of water and concentrated under reduced pressure. The residue was dissolved in 10 L of toluene and concentrated again. This process was repeated two more times. Column chromatographic purification of the crude product was performed on 50 kg silica gel eluted with a gradient of 9-13% v / v EtOAc / hexanes:toluene 1:1 to give 4.23 kg, 83% of compound 67 as a toluene solution.

[0245] [ka]

[0246] To a solution of 4.23 kg (4.16 mol) of 67 in 5.6 L of CHCl and 40 L of MeOH was added 0.72 kg of 10% Pd / C, followed by 0.12 kg (0.63 mmol, 0.15 eq.) of toluenesulfonic acid monohydrate solution, and the mixture was stirred for 24 h at 22° C. After the reaction was judged complete by HPLC analysis, the palladium / carbon was removed by filtration, and the filtrate was used in the next step without further purification.

[0247] To the filtrate was added a solution of 2.97 kg (15.6 mol, 3.75 eq.) toluenesulfonic acid in 4 L MeOH, and the resulting mixture was stirred for 16 h at 22 °C. After the reaction was judged to be complete by HPLC analysis, the mixture was cooled to 0 °C and neutralized by the addition of 1.64 kg (16.2 mol, 3.89 eq.) triethylamine. The solution was concentrated under reduced pressure, and the residue was partitioned between 82 L MTBE and 32 L water. The organic phase was concentrated under reduced pressure, diluted with 10 L toluene, and reconcentrated. This procedure was repeated two more times. Column chromatographic purification of the crude product was performed on 38 kg silica gel, eluting with a gradient of 23-26% v / v EtOAc / hexane:toluene 1:1 to give 2.59 kg of compound 68 as a toluene solution. (67 to 67%).

[0248] [ka]

[0249] A solution of 2.90 kg (3.10 mol) of 68 and 5.24 kg (8.23 mol, 2.65 eq.) of 18 in 30 kg dry toluene was treated with 0.049 kg (0.185 mol, 0.06 eq.) of TBDMSOTf at 0 °C and stirred for 4 h at 0 °C. After the reaction was judged complete by HPLC analysis, 0.104 kg (1.03 mol, 0.128 eq.) of triethylamine was added, followed by 33 L of hexane. The resulting suspension was filtered and the filtrate was washed with 28 L of water, followed by 28 L of 5% aqueous Na2CO3. The toluene phase was concentrated under reduced pressure and the crude product was purified by column chromatography on 58 kg silica gel, eluting with a gradient of 9-20% v / v EtOAc / hexane:toluene 1:1 to give 4.40 kg of the tetrasaccharide intermediate 69 as a toluene solution (75%).

[0250] [ka]

[0251] G. Synthesis of Protected Hexasaccharide (73) Tetrasaccharide intermediate 69 was prepared according to the method described in Example 7. To a solution of 9.7 g (5.15 mmol) of 69 in 60 ml CHCl was added 100 ml MeOH, followed by dropwise addition of 27 ml (0.154 mol, 30 eq.) of 5.7 N HCl in 1,4-dioxane while maintaining the temperature of the mixture below 30° C. The reaction mixture was then stirred at 22° C. for 40 h. After the reaction was judged complete by HPLC analysis, 32 ml (22.9 mmol, 44.7 eq.) of triethylamine was carefully added such that the temperature of the mixture was maintained below 25° C. Water (250 ml) and toluene (200 ml) were added, the mixture was shaken, and the phases were separated. The lower phase was re-extracted with 50 ml toluene, and the combined upper phases were washed with 50 ml water and concentrated under reduced pressure. The crude product was purified by column chromatography on 100 g of silica gel eluted with a gradient of 30–50% v / v EtOAc / hexane to give methylbutyryl 3-O-([3,4,6-tri-O-benzyl-α-D-mannosyl])-(6-O-[2,3,4-tri-O-benzoyl-α-D-mannosyl]-6-O-[3,4,6-tri-O-benzyl-α-D-mannosyl])-2,4-di-O-benzyl-β-D-mannoside 70 (6.35 g, 69%).

[0252] [ka]

[0253] A solution of 1.0 g (0.56 mmol) of 70 and 0.95 g (1.40 mmol, 2.5 eq.) of 19 in 9 ml of dry toluene was treated with 0.02 g (0.075 mmol, 0.14 eq.) of TBDMSOTf at 0° C. and stirred for 1 h at 0° C. After the reaction was judged complete by HPLC analysis, 22 ml (0.158 mmol, 0.28 eq.) of triethylamine was added. The resulting mixture was washed twice with 10 ml of water and concentrated under reduced pressure. The crude product was purified by column chromatography on 15 g silica gel eluted with a gradient of 15-25% v / v EtOAc / hexanes:toluene 1:1 to give 1.75 g of the compound methylbutyryl 3-O-([3,4,6-tri-O-benzyl-α-D-mannosyl]-2-O-[6-O-acetyl-2,3,4-tri-O-benzoyl-α-D-mannosyl])-(6-O-[2,3,4-tri-O-benzoyl-α-D-mannosyl]-6-O-[3,4,6-tri-O-benzyl-α-D-mannosyl]-2-O-[6-O-acetyl-2,3,4-tri-O-benzoyl-α-D-mannosyl])-2,4-di-O-benzoyl-β-D-mannoside 71 as an oil containing residual toluene.

[0254] [ka]

[0255] A solution of 10.0 g (3.5 mmol) of 71 in 40 mL 1,4-dioxane was treated with 60 ml MeOH followed by 3.25 g (14.0 mmol, 4 eq.) (+)-camphorsulfonic acid and the resulting solution was stirred for 100 h at 22° C. After completion of the reaction as judged by HPLC analysis, 3 ml (21.5 mmol, 6.2 eq.) triethylamine was added and the solvent was removed under reduced pressure. The residue was dissolved in 200 ml MTBE and shaken with 200 ml H2O. The phases were separated and the upper phase was concentrated under reduced pressure. Chromatographic purification of the crude product was performed on 114 g of silica gel eluting with a gradient of 14-25% v / v EtOAc / toluene to give 8.24 g of methylbutyryl 3-O-([3,4,6-tri-O-benzyl-α-D-mannosyl]-2-O-[2,3,4-tri-O-benzoyl-α-D-mannosyl])-(6-O-[2,3,4-tri-O-benzoyl-α-D-mannosyl]-6-O-[3,4,6-tri-O-benzoyl-α-D-mannosyl]-2-O-[2,3,4-tri-O-benzoyl-α-D-mannosyl])-2,4-di-O-benzoyl-β-D-mannoside 72 as an oil containing residual toluene.

[0256] [ka]

[0257] To a solution of 0.965 g (0.35 mmol) of 72 in 4 g dry acetonitrile, 0.083 g (0.70 mmol, 2 eq.) of 4,5-dicyanoimidazole was added, followed by 0.315 g (0.91 mmol, 2.6 eq.) of dibenzyl diisopropyl phosphoramidite, and the mixture was stirred at 23° C. for 1 h. After the reaction was judged complete by TLC analysis, 0.5 ml of water was added and the solution was stirred for 15 min. Water (9.5 ml) and 10 ml of MTBE were added, the resulting mixture was shaken, the phases were separated, and the lower phase was shaken with 10 ml of MTBE. The upper phases were combined and concentrated under reduced pressure to give a colorless oil. The residue was dissolved in CH2Cl2, cooled to -20°C, and treated with 0.247 g (1.13 mmol, 3.2 eq.) of 70% 3-chloroperbenzoic acid. After the reaction was judged complete by TLC analysis, 10 ml of 10% aqueous sodium thiosulfate was added and the mixture was warmed to 23°C. The lower phase was separated, shaken with 10 ml of water, and concentrated under reduced pressure. The crude product was purified by column chromatography on 19 g of silica gel eluted with a gradient of 25-50% v / v EtOAc / hexanes to give 0.83 g (72%) of methylbutyryl 3-O-([3,4,6-tri-O-benzyl-α-D-mannosyl]-2-O-[6-O-dibenzylphosphoryl-2,3,4-tri-O-benzoyl-α-D-mannosyl])-(6-O-[2,3,4-tri-O-benzoyl-α-D-mannosyl]-6-O-[3,4,6-tri-O-benzyl-α-D-mannosyl]-2-O-[6-O-dibenzylphosphoryl-2,3,4-tri-O-benzoyl-α-D-mannosyl])-2,4-di-O-benzoyl-β-D-mannoside 73 as a colorless oil.

[0258] [ka]

[0259] H. Synthesis of aminooxyacetamidohydrazide 3-O-([α-D-mannosyl]-2-O-[6-O-phosphoryl-α-D-mannosyl])-(6-O-[α-D-mannosyl]-6-O-[α-D-mannosyl]-2-O-[6-O-phosphoryl-α-D-mannosyl])-β-D-mannoside (77) Compound 73 was prepared according to the method described in Example 8. Glacial acetic acid (100 μL) was added to 73 (64 g, 19.6 mmol) in methanol / THF 1:1 (600 mL) and the product was hydrogenated using an H-cube® with 20% Pd(OH)2 / C at 50° C., 50 bar H2 pressure, and a flow rate of 6 mL / min with recirculation over the catalyst. After 20 h, the reaction was complete by TLC and the solution was concentrated to give 74 as a foam (39.88 g, 93%).

[0260] [ka]

[0261] Methanol (180 mL) was added to 74 (33.8 g, 15.5 mmol) with stirring until dissolved and the solution was cooled in an ice / water bath for 15 min. To this solution was added 64% hydrazine monohydrate (94 mL, 1.24 mol) with stirring. After 30 min, water (120 mL) was added and the solution was allowed to warm to room temperature and stored for 18 h. The solution was concentrated to approximately 100 mL, coevaporated with water (2x100 mL) and the final solution adjusted to approximately 180 mL with water. The solution was extracted with DCM (2x100 mL) and then three 60 mL aliquots were separated on a sephadex size exclusion column. The fractions containing the purest material were combined and lyophilized to give 75 (15.5 g, 80%).

[0262] [ka]

[0263] DMSO (20 mL) was slowly added to 75 (2.5 g, 2.0 mmol) in water (30 mL), followed by Nt-butoxycarbonylaminooxyacetyl 2,3,5,6-tetrafluorophenylate (2.58 g, 7.6 mmol) in DMSO (6 mL) and DHBT (0.65 g, 4 mmol) in DMSO (4 mL). After 18 h, the solution was purified on sephadex size exclusion resin. Fractions were confirmed by charring on silica gel plates and selected fractions were combined and lyophilized to give Nt-butoxycarbonylaminooxyacetamidohydrazide butyryl 3-O-([α-D-mannosyl]-2-O-[6-O-phosphoryl-α-D-mannosyl])-(6-O-[α-D-mannosyl]-6-O-[α-D-mannosyl]-2-O-[6-O-phosphoryl-α-D-mannosyl])-β-D-mannoside 76 (2.57 g, 90%). DCM (30 mL) was added to compound 76 (2.57 g, 1.8 mmol) followed by TFA (16 mL). The mixture was stirred until dissolved (approximately 60 min) and then concentrated to an oil. Water (20 mL) was added and the product was purified on sephadex size exclusion resin. Fractions were confirmed by charring on silica gel plates and selected fractions were combined and lyophilized to give 77 (1.6 g, 67.1%).

[0264] [ka]

[0265] Example 6: Synthesis of a hexasaccharide with a disulfide linker A. Preparation of the Hexasaccharide in Free Acid Form Anhydrous MeOH was added to compound 73 followed by NaOMe and incubated for 4-18 h. The reaction was quenched with glacial acetic acid and the solution was concentrated to a syrup to give 78.

[0266] [ka]

[0267] Compound 78 was dissolved in THF / methanol 1:1 and hydrogenated with Pd / C-H2. The solution was concentrated to a solid, dissolved in water, and saponified with aqueous NaOH. The pH was adjusted to about 4 and purified on Sephadex G-10 to give the free acid 81.

[0268] [ka]

[0269] B. Conjugation of Disulfide Linkers Crude fractions of compound 81 produced by a different method (obtained from Biomira) were converted to the TEA salt by mixing with excess triethylamine (TEA) and subsequently chromatographed on Superdex Peptide (GE Healthcare) using 30% acetonitrile, 0.1% TEA dicarboxylate as the mobile phase. The combined fractions were lyophilized and coupled with NEA in a reaction containing glycan:NEA:EDAC:NHS:HOBt:TEA (1:1:1.5:1:1:1 mol:mol) and incubated overnight with gentle agitation. A portion of the product (0.5 mg) was chromatographed on Superdex Peptide as before and lyophilized to give 82 (0.28 mg).

[0270] [ka]

[0271] Example 7: Optimization of synthesis and oxidation of α-glucosidase conjugate A. Complexation The oligosaccharides were conjugated with recombinant human acid α-glucosidase (rhGAA) to form NeoGAA. The conjugate with oligosaccharides linked mainly through sialic acid residues of r^hGAA was designated as "SAM", and the conjugate with oligosaccharides linked mainly through galactose residues was designated as "GAM".

[0272] NeoGAAβSAM6 was prepared essentially as described in Zhu et al., Biochem J, 389(Pt3):619-628 (2005). The rhGAA samples used in this experiment were found by monosaccharide composition analysis to have approximately 5.2 moles of sialic acid per mole of protein. Briefly, 5 mg / mL rhGAA (Genzyme Corp.) was buffer exchanged into 100 mM sodium acetate pH 5.6 and then reacted with sodium periodate (2, 7.5, or 22.5 mM) for 30 minutes on ice, protected from light. The reaction was stopped by adding glycerol to 2% (vol / vol). To remove small molecular weight by-products from the oxidation reaction, the oxidized rhGAA was buffer exchanged and conjugated with compound 77 (0-120x molar ratio to protein, as shown in Figure 9) for 6 hours at 37°C. All conjugates were buffer exchanged into 25 mM sodium phosphate pH 6.25, containing 2% mannitol and 0.005% Tween-80.

[0273] Similar NeoGAA conjugates were prepared with SAM2 (compound 17, Example 2), SAM3 (compound 35, Example 3), SAM4 (compound 28, Example 4A), linear SAM4 (compound 47, Example 4B), and αSAM6 (oligosaccharide 103) using 7.5 mM periodate and varying the molar ratio of oligosaccharide to rhGAA.

[0274] Alternative conjugation methods were also performed: specifically, hexasaccharides bearing either aminoxy, hydrazide or thiol reactive linkers were attached to rhGAA via Cys374, lysine, sialic acid or galactose residues.

[0275] Lysine conjugation was performed by modifying the lysine residues of rhGAA with 4-formylbenzoate succinimidyl (SFB; Solulink Corp.) followed by conjugation with oligosaccharides. Briefly, rhGAA was first buffer exchanged into 50 mM sodium phosphate pH 7.2 containing 150 mM sodium chloride. The buffered rhGAA was then treated with freshly prepared SFB to GAA molar ratio of 20:1 (SFB). The mixture was incubated at room temperature for 30 min, then it was buffer exchanged into 100 mM sodium acetate pH 5.5 and conjugated to hydrazide hexasaccharides at room temperature for 2 h, or the SFB-modified GAA was buffer exchanged into 100 mM sodium acetate pH 5.6 and conjugated to aminoxy hexasaccharides at 37° C. for 6 h.

[0276] Cysteine-based conjugation was carried out by reaction with thiol-reactive NEA-hexasaccharide 82 (Example 6I). NEA-modified hexasaccharide 82 was reconstituted in water and incubated with rhGAA (15:1 molar ratio of neoglycan to rhGAA) in 50 mM sodium phosphate and 50 mM hydroxylamine pH 7.2 for 2 hours at 25°C. The pH was adjusted to 6.2 with 50 mM sodium phosphate pH 4.1 and incubation continued overnight. The product was purified by centrifugal diafiltration against 25 mM sodium phosphate pH 6.2. Less than 1 mol of M6P was introduced per mol.

[0277] Direct conjugation via Cys374 was unsuccessful, but a homobifunctional thiol-specific reagent, 1,4-di-(3'-[2-pyridyldithio]-propionamido)butane (DPDPB) with a 19.9 Å spacer arm, was tested to provide a more solvent-accessible thiol group at position 374 prior to conjugation with oligosaccharides. A 60-fold molar excess of DDPPB was reacted with rhGAA in the presence of either 10% DMSO or 10% propanol as cosolvent. This caused strong aggregation as detected by light scattering. Reactions in the presence of 20% acetonitrile also showed aggregation, but the absorbance at 344 nm of ultrafiltrates of the reaction mixture was consistent with quantitative modification of the cysteine. Reduction of the acetonitrile concentration to 10% reduced the amount of aggregation, but the extent of modification was low.

[0278] Another thiol-based method was carried out by the introduction of a thiol group at lysine residues. A protected thiol was introduced at the lysine residues by enzymatic reaction with 100-fold molar excess of SATA-dPEG4-NHS (Quanta Biodesign) in sodium phosphate pH 6.2 for 4 h at 25 °C, and purified by overnight dialysis against the same buffer. The purified product was then reacted with NEA-oligosaccharide 82 under the conditions described above for the cysteine-based conjugates to give a lysine-thiol conjugate, which showed about a 10-fold increase in Man-6P content (about 5 glycans were conjugated).

[0279] The stability of the ricin conjugate with hydrazide was assessed for up to 14 days at 37°C by measuring intact protein molecular weight and M6P content. The conjugate was not stable as over 50% of the neoglycans were lost over 14 days. Ricin-mediated aminoxy conjugates were prepared as above using 0, 16.6, 25, 33 and 40 molar excesses of hexasaccharide over rhGAA. Only about 31% of the total ricin was conjugated (or 5 neoglycans were conjugated), but the conjugation was saturated at a 16.6-fold molar excess. High aggregation levels were also observed in some preparations. PEGylated SFB was tested but did not show any reduction in aggregation.

[0280] Galactose conjugation (GAM) was performed by first pretreating rhGAA with 20 mU / mg of sialidase from Clostridium perfringens for 6 h at 37°C in 25 mM sodium phosphate, pH 6.25, containing 2% mannitol and 0.005% Tween-80. After disialylation, the protein was treated with 1–10 μg / mg of galactose oxidase (GAO) and 2 U / mg of catalase (Sigma) in the same buffer overnight at 37°C. It was then repurified using Poros50D (anion exchange) chromatography to remove neuraminidase and catalase. The product treated with both enzymes was diluted with an equal volume of dH2O and then applied to a Poros50D column pre-equilibrated with 10 mM sodium phosphate buffer, pH 6.9. The column was washed with 10 mM sodium acetate buffer, pH 5.0, and rhGAA was eluted with 150 mM sodium acetate buffer, pH 5.0, and conjugated with aminoxy hexasaccharide at various molar ratios for 6 hours at 37°C.

[0281] GAM conjugation was saturated with a 16.6-fold molar excess of hexasaccharide over GAA, with approximately 6–7 glycans conjugated. The level of aggregation was low. After desialylation, no sialic acid was detected. Meanwhile, almost no galactose was detected after galactose oxidase treatment. In some instances, 20–30% of the galactose residues were overoxidized to form galacturonic acid that was not linked to oligosaccharides. Titration of GAO showed that above 1 μg / mg GAO reduced glycan conjugation. When GAO was greater than 2 μg / mg GAO, there was a clear increase in the amount of overoxidation product of galacturonic acid. The maximum amount of conjugation was achieved at 1–2 μg GAO per mg rhGAA (Figure 10E - Content of monosaccharides, including Man-6P, Gal, and GalA, in GAM conjugates after titration of GAO). When 0.5–2 μg of GAO per mg of GAA was used, most of the complexation was observed as the Man-6P content of the protein. Using less or more GAO resulted in either less galactose or more GalA.

[0282] The amount of bis-M6P hexasaccharide glycan conjugated to NeoGAA was quantified by M6P content analysis and MALDI-TOF. For M6P quantification, samples were filtered five times using Amicon4, 50,000 MWCO centrifugal filter units to buffer exchange and remove potential excess glycans. Eighty micrograms of each rhGAA or NeoGAA sample was hydrolyzed with 6.75 M TFA for 1.5 hours at 100°C. Samples were cooled, dried in a Speed ​​Vac, and reconstituted in 200 μL of distilled water. Reconstituted samples were again dried in a Speed ​​Vac and reconstituted in 200 μL of 50 mM citric acid pH 2.0. Samples were filtered through S Mini H cartridges (Sartorius), which were equilibrated with sodium citrate pH 2.0 to remove impurities from the hydrolysate. Ribose-5-phosphate was added to all samples and standards as an internal standard. 50 μL of hydrolysate was injected into a Dionex HPLC and analyzed by high pH anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD). Quantitation was performed using a calibration curve constructed with hydrolyzed standards of M6P. The degree of conjugation was then calculated based on the known molar ratio of 2 moles of M6P per mole of glycan.

[0283] MALDI-TOF MS analysis was performed on a VoyagerDE-PRO mass spectrometer in in-line mode. A 1:5 dilution in 0.1% formic acid in water was performed on all samples and standards, followed by a 1:1 dilution in saturated sinapinic acid in 50% acetonitrile / 0.1% TFA solution. 1 μL of this mixture was used as the target. Samples, references, and BSA compensation controls were analyzed in triplicate. A two-point calibration was performed using the (M+H)+ and dimer ions of BSA. The degree of conjugation of each NeoGAA sample was calculated based on the difference in molecular weight between the sample and the oxidized rhGAA control (no glycan added), taking into account that the measured glycan molecular weight was 1323 g / mol.

[0284] FIG. 9A shows the results of experiments with the di-, tri-, tetra-, and hexasaccharide conjugates described above.

[0285] FIG. 9B provides results for βSAM6 conjugates prepared with different amounts of periodate. The oligosaccharide levels required to achieve saturation of the conjugation reaction were proportional to the amount of periodate used during the oxidation step (FIG. 9B, top panel). With 2 mM periodate, a sample of rhGAA with approximately 5.2 moles of sialic acid reached saturation at nearly a 25-fold molar excess of hexasaccharide to protein (at a 4.8-fold molar excess to sialic acid). With 7.5 mM periodate, saturation was reached at a 33-fold molar excess of glycan. With a 120-fold molar excess of glycan, saturation was reached but not achieved with rhGAA oxidized with 22.5 mM periodate. The maximum level of conjugation achieved was also different for samples prepared with different levels of periodate. With 7.5 and 22.5 mM periodate, approximately 8.5 and 10.5 moles of glycan were incorporated per mole of protein, respectively. After oxidation with 2 mM periodate, the achievable conjugation level is approximately 5 moles of glycan per mole of protein, which is close to the number of sialic acid residues in the starting material.

[0286] The glycan titration experiment was repeated at 2 mM periodate with rhGAA, which gave an initial sialic acid level of about 7.2 moles per mole of protein (FIG. 9B, lower panel). A conjugation level of about 7 moles of glycan per mole of protein was achieved with a greater than 33-fold molar excess of glycan over protein (about 4.6-fold molar excess compared to sialic acid).

[0287] B. Reduced aggregation Certain conjugation methods cause protein aggregation. In neoGAA, two methods have been developed to reduce aggregation: 1) hydrophobic interaction chromatography (HIC) using various HIC chromatography supports, and 2) metal chelation.

[0288] A 3 g batch of NeoGAA was prepared and used to evaluate HIC and copper columns for clump removal. The HIC columns evaluated in flow-through mode were: Butyl 650C and 650M, Hexyl 650C, Phenyl 6FF, Capto Octyl, and Capto Phenyl. Hexyl and Capto Phenyl showed comparable results with recoveries of 87.5% and 90.4%, and clump reductions from 3.2% (initial levels) to 1.4% and 3.9% (initial levels) to 1.6%, respectively. See Table 2.

[0289] [Table 5]

[0290] The operating conditions of the copper chelating column (GE or Tosoh) were also established in either flow-through or bind-elute mode. A 7 ml metal chelating FF column (ID, 7 ml) loaded with copper was first loaded with 10 mg / ml of complexed GAA and evaluated in bind-elute mode. 87% of NeoGAA was recovered with 1.2% aggregates when eluted from the column with 175 mM glycine, 100 mM acetate, pH 5.5 as elution buffer at room temperature. Glycine higher than 175 mM was required at 8 °C to elute from the column with satisfactory recovery. In flow-through mode (Table 3), an excellent recovery of 92% was achieved with 150 mM glycine, 100 mM acetate, pH 5.5 as elution buffer, and aggregates were reduced from 3.2 to 1.2%.

[0291] [Table 6]

[0292] Imidazole (7.5, 8 and 10 mM) was also tried as an elution buffer for the metal chelating 6FF column. Approximately 8 mM imidazole was required to elute the column. Since imidazole does not elute copper from the column, it was not necessary to condition the column or create an empty space above the column with EDTA. A column capacity of 15 mg per ml of NeoGAA was achieved.

[0293] A copper-loaded TosoAF-Chelate 650M column was also evaluated. In bind-elute mode, a column capacity of 15 mg / ml was achieved with 94.1% elution and 1.2% aggregates using 8 mM glycine. In flow-through mode, a capacity of 33.6 mg / ml was achieved with 90.6% recovery and 1.2% aggregates using 50 mM glycine in this elution buffer.

[0294] C. Oligosaccharide Analysis These experiments demonstrated that use of >2 mM periodate resulted in incorporation of NeoGAA glycans above the starting sialic acid levels in the protein, indicating that non-sialic acid moieties were oxidized. To measure the level of oxidation at other carbohydrate sites by periodate, a series of periodate titration experiments were performed to observe the levels of other monosaccharide residues.

[0295] To measure sialic acid content, samples were acid hydrolyzed with 0.5 M formic acid at 80°C for 1 h. Released sialic acid was analyzed by high pH anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) on a Dionex CarboPac PA1 column in 100 mM sodium hydroxide over 20 min using a 50-180 mM sodium acetate gradient. Results are expressed as moles of sialic acid (NANA or NGNA) per mole of rhGAA or NeoGAA and were determined from a calibration curve of authentic commercial sialic acid standards.

[0296] Levels of neutral monosaccharides, including fucose, galactose, GlcNAc, and mannose, were measured by hydrolysis of 100 μg of rhGAA or NeoGAA in 1 M TFA at 110 °C for 2 h. Following hydrolysis, the tubes were cooled on ice, centrifuged at 10,000 rpm for 1 min, and evaporated to dryness in a Speed ​​Vac. Released monosaccharides were resuspended in 250 μL of water, vortexed, and filtered using Millipore Ultrafree-MC filter tubes (10,000 MWCO). Released monosaccharides were analyzed by high pH anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) on a CarboPacPA1 column. Quantification was performed in a similar manner using a calibration curve of hydrolyzed monosaccharides.

[0297] The results of the above experiments are shown in Figure 10A. The results suggested that sialic acid was the monosaccharide most susceptible to oxidation. Low levels of fucose destruction could be detected at 2 mM periodate, and the amount could be measured and reproduced at 5 mM and above. Slight oxidation of mannose could only be detected at 7.5 mM periodate and above.

[0298] To confirm the presence of oxidized sialic acid, fucose, and mannose, fragmentation mass spectrometry was performed on oligosaccharides released from rhGAA oxidized with 7.5 mM periodate. N-linked oligosaccharides in rhGAA and NeoGAA were released by digestion with PNGaseF overnight in 50 mM sodium phosphate pH 7.0 and 10 mM M-mercaptoethanol. Released oligosaccharides were clarified by biodialysis (MWCO 500 Da) with water changes. Dialyzed samples were dried in a speed-vac concentrator and reconstituted in 110 μL of a solution of 10 mM ammonium formate pH 4.0 in 50% acetonitrile and 50% water. Samples were analyzed in an acetonitrile-water gradient and 10 mM ammonium formate pH 4.0 using a TSK GelAmide-80 column (100 μL injection into 2x100 mm, 5 μm particle size) with in-line MS detection (QStar quadrupole time-of-flight, LCT Premier time-of-flight, and LTQ linear ion trap instruments).

[0299] To analyze the oligosaccharide structures, the oligosaccharides were dried and fluorescently labeled with anthranilic acid (AA). The AA-labeled oligosaccharides were separated by normal-phase HPLC on a TSK Gelamide 80 column using an acetonitrile / water gradient and fluorescence detection. MS fragmentation analysis was performed in-line on an LTQ XL linear ion trap mass spectrometer in positive ion mode. Spectra were scanned from 400 to 2,000 m / z, with the collision energy set to 35 (default value, unless otherwise indicated in the text) and activationQ set to 0.25.

[0300] Sialic acid: Complete oxidation of sialic acid (at both C7,8 and C8,9 linkages) results in a 62 Dalton reduction in mass. Oxidation of fucose and mannose results in an initial 2 Dalton reduction (oxidation of C2,3 or C3,4 linkages), followed by oxidation of the remaining vicinal diols, resulting in a 30 Dalton reduction. Reductive amination of bicarbonate aldehyde with AA results in the loss of oxygen, causing a net molecular weight increase of 121.1 Daltons for each additional AA. The theoretical and observed molecular weight changes in rhGAA oligosaccharides after oxidation of sialic acid, fucose, and mannose are shown in Table 4.

[0301] [Table 7]

[0302] A variety of ions corresponding to oxidized and AA-derivatized oxidized sialic acid, fucose, and mannose oligosaccharide species were observed. In addition to derivatization with GlcNAc at the reducing end of all released oligosaccharides, AA was derivatized in proportion to the number of reactive aldehyde species present, i.e., 1:1 with oxidized sialic acid and 2:1 with oxidized mannose and fucose.

[0303] The mass spectrum in Figure 10B shows the detection of four ions corresponding to rhGAA oligosaccharides with oxidation and AA derivatization at the C7 position of sialic acid. Two ions related to the oxidation of sialic acid (m / z 1057 and 1130) were selected for further MS / MS fragmentation analysis. The fragmentation pattern of m / z 1057 is shown in Figure 10C, and each ion is annotated with the hypothesized entity. The fragmentation ions m / z 716, 1032, 1235, 1397, 1584, and 1747 were selected from the MS3 analysis. MS 3The spectrum was consistent with the postulated oligosaccharide structure, containing terminal oxidation of biantennary glycans and AA-labeled sialic acid. In particular, the release of a fragment at m / z 351 confirmed the attachment of AA to the C7 form of sialic acid. In the analysis of all samples, only the C7 form of oxidized sialic acid was observed. No evidence for the presence of oxidized sialic acid at the C8 position was observed.

[0304] Fucose oxidation: Table 5 lists the theoretical and observed masses of AA-derivatized, oxidized A1F and A2F.

[0305] [Table 8]

[0306] The fragmentation pattern of the parent ion at m / z 1250.4 is shown in Figure 10D and is consistent with that predicted for an AA-labeled, monosialic acid, single-chain, fucosylated core oligosaccharide with oxidized sialic acid and oxidized fucose. Major fragment ions were observed at m / z 716, 1397, 1621, and 1783. These ions were analyzed by MS to confirm the hypothesized material. 3 Selected for analysis were m / z 1621 and 1783 MS 3 In the spectrum, the ion fragmentation pattern confirmed the loss of 195 Daltons from the parent ion (from parent ions 1621 and 1783 to 1426 and 1588, respectively). This change in molecular weight is consistent with cleavage between the C1 and oxygen atoms of the oxidized fucose, resulting in the loss of a derivatized anthranilic acid attached to C4. In addition, further fragmentation and the loss of another derivatized anthranilic acid attached to C3 were observed as the loss of 386 Daltons from the parent ion (1235 and 1397 m / z from parent ions 1621 and 1783, respectively).

[0307] The MS fragmentation pattern of the oxidized rhGAA oligosaccharide A1F showed derivatization of C3,4 of the anthranilic acid-linked fucose, confirming that oxidation by periodate occurred. No evidence of oxidation of the C2-C3 bond was observed. Conjugation of the bis-M6P hexasaccharide glycan to the oxidized rhGAA resulted in a net gain of 1305.3 daltons during the condensation reaction.

[0308] To confirm the integrity of the conjugated oligosaccharide structures, high-precision MS analysis of the released native oligosaccharides was performed. Oligosaccharides from rhGAA and NeoGAA SAM6 produced with 2 and 7.5 mM periodate were released using PNGase F and normal phase HPLC (TSK Gelamide-80 column) in an acetonitrile-water gradient with 10 mM ammonium formate pH 4.0. Mass spectrometric detection of the glycans was performed in-line, negative ion mode, using a QStar or LCT time-of-flight mass spectrometer.

[0309] The following table summarizes the identification of native N-linked oligosaccharide peaks from rhGAA oxidized with 2 and 7.5 mM periodate, and in SAM6 produced with 2 and 7.5 mM periodate, based on high performance MS / TOF analysis. "Ox" indicates the number of oxidation sites, and "Conj" indicates the number of conjugated bis-M6P hexasaccharide glycans. Theoretical masses were calculated from the monoisotopic molecular weights of the theoretical oligosaccharide structures, and the theoretical and observed m / z of the corresponding charge states are shown.

[0310] [Table 9]

[0311] [Table 10]

[0312] [Table 11]

[0313] [Table 12]

[0314] [Table 13]

[0315] Mass accuracies of better than 20 ppm were observed for all oligosaccharide species. MS results were consistent with monosaccharide composition analysis showing that oxidation of sialic acid was complete at 1 mM periodate or higher. Some oxidation of mannose and fucose was also evident. Ions corresponding to the attachment of 1 and 2 moles of glycan per oxidized mannose and / or fucose were observed, suggesting that both respective aldehyde species are reactive towards glycans, as observed with AA.

[0316] Some conjugation of high mannose structures (oligomannose 5 and 6) was detected in material treated with 2 and 7.5 mM periodate. In material conjugated with 2 mM periodate, 0- or 1-conjugated glycans were observed in the A1 (monosialylated) species, whereas ions corresponding to 0-, 1-, 2-, and 3-conjugated glycans were observed in the A1 species at 7.5 mM SAM6. This result suggests that with 7.5 mM (but not 2 mM) periodate, some oxidation and conjugation of core mannose and / or galactose residues occurs in the A1 structure.

[0317] For the A2 and A2F species (disialic acid, bibranched, ±fucose), mono- and bi-conjugated species were observed in the 2 and 7.5 mM periodate samples. Evidence of tri-conjugation with oxidized mannose was observed only in the 7.5 mM periodate-treated sample, but not in the 2 mM treatment, consistent with conjugation via fucose at high periodate concentrations.

[0318] FIG. 11A shows HPLC analysis of oligosaccharides released from rhGAA and NeoGAA. For the rhGAA control, the majority of N-linked oligosaccharide species eluted at 11-13 min, a region corresponding to oligosaccharides that were neither phosphorylated nor conjugated. For the NeoGAA oligosaccharides, bi-conjugated species eluted at 19-20 min, mono-conjugated species at 15-18 min, and oxidized / unmodified oligosaccharides at 10-13 min. For the SAM6 sample generated with 7.5 mM periodate, nearly half of the oligosaccharides eluted in a region corresponding to bi-conjugated species, and roughly one-third of the oligosaccharides in the 2 mM periodate-treated sample were bi-conjugated. The elution profile of these samples was consistent with the conjugation levels measured by MALDI-TOF and mannose-6-phosphate content analysis (approximately 7 and 9 moles of glycan conjugated per mole of NeoGAA for 2 and 7.5 mM periodate, respectively, to generate SAM6).

[0319] To provide better visualization and qualitative comparison of the oligosaccharide structures present, the released oligosaccharides were analyzed by high pH anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD). Samples were analyzed by HPAEC-PAD on a Dionex CarboPac PA100 column using a sodium acetate / 100 mM sodium hydroxide gradient. Oligosaccharide peak material was confirmed by analysis by normal phase HPLC with offline fraction collection, dialysis vs. water, and in-line MS analysis.

[0320] Figure 11B shows representative HPAEC-PAD data including peak material (as measured by MS), and Figure 11C shows oligosaccharide profiling by HPAEC-PAD of 2 and 7.5 mM periodate-treated rhGAA and NeoGAASAM6 samples.

[0321] D. Analysis of the rhGAA protein backbone after periodate treatment To investigate protein modifications of the protein backbone of NeoGAA, peptide mapping LC / MS was performed. NeoGAASAM6 produced with 0, 2, 7.5 and 22.5 mM periodate was prepared with trypsin and analyzed by reversed-phase HPLC with an LCT time-of-flight mass spectrometer. Possible peptide modifications, such as oxidation of cysteine, methionine, tryptophan, tyrosine and histidine residues, as well as deamidation of asparagine, were evaluated using BioPharmalynx software. The only significant modification detected was methionine oxidation at several different sites. The oxidation levels of peptide T13 (including methionines 172 and 173) after treatment with 0, 2 and 22.5 mM periodate are shown in Figure 12.

[0322] Significant levels of oxidation were found at methionine residues 122, 172, and 173. Oxidation of these methionine residues was confirmed by LC / MS / MS analysis. A low level of oxidation was also observed to occur at methionine 363 in a periodate-dependent manner. In an attempt to minimize periodate oxidation, the periodate concentration was titrated at levels from 1 to 7.5 mM to oxidize the most sensitive site (peptide T13) monitored by LC / MS. Significant levels of methionine oxidation were observed at periodate concentrations greater than 1 mM, indicating that the methionines in rhGAA are as susceptible to oxidation as the sialic acid residues.

[0323] During GAM conjugation, galactose oxidation by GAO resulted in approximately 26% oxidation of Met172 / 173. Methionine oxidation was eliminated when catalase was included in the oxidation reaction at 2 and 50 units / mg GAA.

[0324] Example 8: In vitro characterization of GAA complexes NeoGAA SAM2 was prepared as described in Example 7 using compound 17 from Example 2 and 7.5 mM periodate. Galactose-linked NeoGAA GAM2 was prepared by treating rhGAA with galactose oxidase prior to conjugation with disaccharide 17. Similarly, trisaccharide NeoGAA SAM3 (compound 35, Example 3), tetrasaccharide NeoGAAs SAM4 (compound 28, Example 4A), and linear SAM4 (compound 47, Example 4B) were also prepared. Additionally, hexasaccharide NeoGAAβ SAM6 was prepared using compound 77 at 2 and 7.5 mM periodate as described in Example 7. Additional hexasaccharide conjugates αSAM6 (α-linked, conjugated via sialic acid residues) and GAM6 (conjugated via galactose residues) were similarly prepared.

[0325] A. Specific activity: Activity assays were performed by monitoring the rate of hydrolysis of the synthetic substrate p-nitrophenyl-D-α-glucopyranoside (p-NP) catalyzed by rhGAA and NeoGAA. The released chromophore was measured by absorbance at 400 nm under alkaline conditions. One unit of activity is defined as the amount of enzyme required to hydrolyze 1 μmol of p-nitrophenyl-D-α-glucopyranoside to p-nitrophenol per minute at 37°C under the defined assay conditions.

[0326] The specific activities of NeoGAA SAM2, SAM3, SAM4, linear SAM4, αSAM6, and βSAM6 are shown in Figure 13. Additionally, the specific activity of conjugates produced using the SAM vs. GAM method was evaluated. There was an inverse correlation (p<0.001) between the number of M6P relative to GAA and the specific activity of NeoGAA conjugates produced at small and large scales, with 16.6-fold molar excess of oligosaccharides per GAA. In separate experiments where the NeoGAA concentration was titrated during conjugation (2.5-33-fold molar excess of oligosaccharides), a loss of GAA activity was also observed with increasing M6P content in the SAM or GAM conjugates. For SAMs with 49-81% GAA activity (compared to control), the various NeoGAAs contained 6-8 molecules of oligosaccharides per protein. The GAM conjugates had 67-92% activity and contained 4-6 oligosaccharides per protein.

[0327] B. M6P Receptor Binding: The functional effect of the complex was assessed by monitoring the binding of NeoGAA to the soluble cation-independent mannose-6-phosphate receptor (sCIMPR) by Biacore and M6P receptor affinity-column HPLC, and by uptake in L6 myoblasts. Purified from bovine serum, sCIMPR contains the extracellular domains A to X and lacks the membrane-transducing portion.

[0328] For Biacore analysis, sCIMPR was amine-coupled to a CM-5 chip and 10 μg / mL of NeoGAA sample was immobilized on the surface and eluted with increasing concentrations of mannose-6-phosphate. Affinity was quantified as the concentration of M6P required to displace 50% of the bound NeoGAA (EC50). The method was used to monitor the effect of binding and oxidation on receptor affinity.

[0329] The results of the Biacore analysis are shown in Figure 14. Injection of 10 μg / mL NeoGAA onto a Biacore chip with immobilized sCIMPR caused an increase in response of approximately 250 RU, while the same amount of rhGAA caused a deviation of approximately 100 RU. Furthermore, approximately 10-fold higher M6P concentrations were required to elute NeoGAA than rhGAA (EC50 values ​​of approximately 0.1 vs. 1.0 mM for rhGAA and NeoGAA, respectively). A linear relationship was observed (R-squared > 0.95) between the EC50 values ​​and the binding levels of NeoGAA produced with 2 and 7.5 mM periodate. In the conjugation range investigated (1.6–4.7 mol glycan / mol, NeoGAA, prepared with 2 mM periodate, and 1.0–8.5 mol glycan / mol, prepared with 7.5 mM NaIO4), the effect of conjugation level on binding affinity was similar for NeoGAA prepared with 2 and 7.5 mM periodate.

[0330] M6P receptor binding was assessed by HPLC using an M6P receptor column prepared by immobilizing sCIMPR on PorosEP resin and then packing into an analytical HPLC column. rhGAA and NeoGAA were eluted with 0.25, 0.85, 5, and 20 mM M6P (Figure 15A and B). In one experiment, SAM2 and GAM2 were compared to βSAM6 and GAM6 (Figure 15C). SAM6 and GAM6 required 20 mM M6P before the majority of the material was eluted (>95% of the complex bound to the column). SAM2 and GAM2 bound less tightly and were largely eluted at 5 mM M6P (>95% bound to the column).

[0331] Additionally, the NeoGAA conjugates SAM2, SAM3, SAM4, linear SAM4, and αSAM6 were evaluated for M6P receptor binding (FIG. 15D). The majority of SAM2, SAM3, and both SAM4 conjugates eluted at 5 mM M6P, whereas both SAM6 conjugates required 20 mM M6P.

[0332] NeoGAA conjugates with various amounts of conjugation were evaluated (Figure 15E). The percentage of NeoGAA in the bound fraction was consistently >95% for preparations with >2.0 moles of glycan per mole of NeoGAA conjugated. In the few fractions with low conjugation levels (1.0-1.7 moles of glycan), the bound fraction was 75-90%. M6P column analysis data for NeoGAA also showed a higher amount of high affinity species than rhGAA. Specifically, the majority of the bound rhGAA was eluted at 0.2 mM M6P, and 20 mM M6P was required to elute NeoGAA from the column. The overall effect of conjugation level on the percentage of high affinity species was similar to 2.0-7.5 mM periodate treatment.

[0333] Figure 15F shows the effect of various amounts of M6P. SAM6 complexes contained the following amounts of M6P: SAM6-1 (4.9 moles M6P per mole rhGAA), SAM6-2 (7.4 moles M6P per mole GAA), SAM6-3 (10.5 moles M6P per mole rhGAA), SAM6-4 (11.2 moles M6P per mole rhGAA) and SAM6-5 (16.6 moles M6P per mole rhGAA). Statistical significance is indicated by ^, * and ***, representing p<0.05 compared to 100 mg / kg rhGAA, SAM6-1, SAM6-3, respectively.

[0334] C. Intracellular migration by L6 myoblasts L6 myoblast uptake assays were performed as described in Zhu et al., J. Biol. Chem. 279:50336-50341 (2004) and demonstrated that rhGAA and NeoGAA target myoblasts via the cation-independent mannose-6-phosphate receptor (CIMPR) pathway. In the L6 myoblast uptake assays, rhGAA and NeoGAA were added to medium + / - 5 mM M6P in wells containing L6 myoblasts and incubated overnight for a pre-determined period. After incubation, cells were lysed and assayed for activity using 4-MU glucoside substrate and protein concentration by microBCA assay to generate enzyme dose-response curves.

[0335] The results of the L6 myoblast uptake assay are shown in Figure 16. The SAM2 and GAM2 conjugates showed significantly higher uptake than unmodified rhGAA, but not as high as the diphosphorylated SAM6 or GAM6 conjugates (Figure 16, top). The uptake of NeoGAA was also tested with SAM2, SAM3, SAM4, linear SAM4, and αSAM6 (Figure 16, bottom). In a similar experiment, the lysine-thiol conjugate of Example 7 caused an approximately 8-fold increase in uptake.

[0336] Example 9: In vivo effects of novel GAA complexes The in vivo effects of certain NeoGAA complexes were investigated using the GAA knockout mouse model described by Raben et al., J. Biol. Chem. 273(30):19086-92 (1998). Groups of six mice each were treated once a week for four weeks as follows:

[0337] [Table 14]

[0338] Samples were collected from the heart, quadriceps, and triceps and the glycogen content of the tissues was measured. The results for SAM2, SAM4, and SAM6 animals are shown in Figures 17, 18, and 19, respectively. The experiment was repeated in a group of 12 animals using the SAM6 complex, which was found to be 5-fold more potent than unmodified rhGAA.

[0339] SAM and GAM hexasaccharide conjugates were compared using groups of six mice receiving vehicle, 20, 60, or 100 mg / kg rhGAA, or 4, 12, or 20 mg / kg SAM6 or GAM6 once a week for 4 weeks. The heart, quadriceps, triceps, diaphragm, and psoas muscles were isolated and analyzed for glycogen content. The results of this study are shown in Figure 20. For the pharmacokinetic and pharmacodynamic studies, 30 GAA knockout mice (15 males, 15 females) aged 3 to 6 months were obtained from Charles River Laboratories, Wilmington, MA. Each dose group contained 5 males and 5 females. Animals were housed in groups and maintained at 25°C with constant humidity and a 12-hour light-dark cycle. All animals had free access to food (PicoLab® Rodent Diet 20) and water. Animals were randomly divided into three dose groups, 5 males and 5 females per group, for a total of 10 mice per dose. Each group received a single intravenous dose of rhGAA, GAM and SAM complexes at 20 mg / kg. Blood samples for pharmacokinetic analysis were collected at 5, 15, 30, 60, 120, 240 and 480 min post-dose via the retro-orbital plexus in conscious mice. Serum rhGAA concentrations were measured using a GAA activity assay. The results are shown in Figure 20B.

[0340] Example 10: Synthesis of acid sphingomyelinase complex Recombinant human acid sphingomyelinase (rhASM) expressed in a baculovirus expression system or in Chinese hamster ovary cells has a C-terminal cysteine ​​with a free thiol group. See Lansmann et al., Eur. J. Biochem. 270:1076-1088 (2003) and Qiu et al., J. Biol. Chem. 278:32744-32752 (2003). rhASM can be conjugated via the free thiol group to any of the oligosaccharides 1-127, which contain a linker and a thiol reactive group, according to the methods described in U.S. Provisional Patent Application No. 60 / 885,457, or in Example 6.

[0341] Example 11: Synthesis of α-L-iduronidase conjugate α-L-iduronidase is conjugated to any of the oligosaccharides 1-127, which contain a linker containing a propionaldehyde reactive group, according to the method described by Lee et al., Pharm. Res. 20:818-825 (2003). α-L-iduronidase and oligosaccharides are conjugated in the presence of sodium cyanoborohydride as a reducing agent at room temperature, pH 5.5, for 1 day. Small molecules are then removed from the reaction mixture by dialysis or diafiltration.

[0342] All references cited herein are incorporated herein by reference in their entirety. In the event that a reference incorporated by reference and a patent or patent application conflicts with an invention contained herein, the present specification supersedes any conflicting material.

[0343] All numbers expressing quantities of ingredients, reaction conditions, and the like used in the specification and claims should be understood to be modified in all instances by the word "about," which means, for example, ±5%. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and appended claims are approximations that vary depending on the desired properties sought by the specification. At the very least, and without any intention to limit the application of the doctrine of equivalence to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and the manner in which it is expressed.

[0344] Many modifications and variations of this invention, apparent to those skilled in the art, can be made without departing from the scope and spirit of the invention. The specific embodiments described herein are set forth by way of example only and are not intended to be limiting in any way. It is intended that the specification and examples be considered as exemplary only, with the true scope and spirit of the invention being indicated by the following claims.

Claims

1. A compound of the following formula: [Formula 1]

2. A compound of the following formula: [Case 2]

Citation Information

Patent Citations

  • Novel oligomannoside and its preparation

    JP1984036691A

  • Oligosaccharide conjugates for cellular targeting

    WO2008089339A2

  • Oligosaccharides comprising an aminooxy group and conjugates thereof

    WO2008089403A2